<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>626</serviceExecutionTime><Drug id="2911"><DrugName>daptomycin</DrugName><DrugNamesKey><Name id="42753961">Cidecin</Name><Name id="42764929">Cubicin</Name><Name id="42753962">Dapcin</Name><Name id="42753963">daptomycin</Name></DrugNamesKey><DrugSynonyms><Name><Value>Cidecin</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Dapcin</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>daptomycin</Value><Types><Type>USAN</Type><Type>BAN</Type><Type>INN</Type></Types></Name><Name><Value>deptomycin</Value></Name><Name><Value>LY-146032</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Cubicin</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>A-21978C</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>MK-3009</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>103060-53-3</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="17810">Eli Lilly &amp; Co</CompanyOriginator><CompaniesPrimary><Company id="27398">Kuhnil Pharmaceutical Co Ltd</Company><Company id="24019">MSD Japan</Company><Company id="29954">TTY Biopharm Co Ltd</Company><Company id="18077">Merck &amp; Co Inc</Company><Company id="29943">Medison Pharma Ltd</Company><Company id="19858">Sunovion Pharmaceuticals Inc</Company></CompaniesPrimary><CompaniesSecondary><Company id="14190">AstraZeneca plc</Company><Company id="15385">Chiron Corp</Company><Company id="16450">Gilead Sciences Inc</Company><Company id="17810">Eli Lilly &amp; Co</Company><Company id="21697">Cubist Pharmaceuticals Inc</Company><Company id="23137">Novartis AG</Company><Company id="29723">Sunovion Pharmaceuticals Canada Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="2911" type="Drug"><TargetEntity id="111916" type="siDrug">Daptomycin</TargetEntity></SourceEntity><SourceEntity id="14190" type="Company"><TargetEntity id="4295894341" type="organizationId">AstraZeneca PLC</TargetEntity></SourceEntity><SourceEntity id="15385" type="Company"><TargetEntity id="5036161975" type="organizationId">Chiron Corp</TargetEntity></SourceEntity><SourceEntity id="16450" type="Company"><TargetEntity id="4295906595" type="organizationId">Gilead Sciences Inc</TargetEntity></SourceEntity><SourceEntity id="17810" type="Company"><TargetEntity id="4295904414" type="organizationId">Eli Lilly and Co</TargetEntity></SourceEntity><SourceEntity id="18077" type="Company"><TargetEntity id="4295904886" type="organizationId">Merck &amp; Co Inc</TargetEntity></SourceEntity><SourceEntity id="19858" type="Company"><TargetEntity id="4295907900" type="organizationId">Sunovion Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="21697" type="Company"><TargetEntity id="4295906092" type="organizationId">Cubist Pharmaceuticals LLC</TargetEntity></SourceEntity><SourceEntity id="23137" type="Company"><TargetEntity id="4295890628" type="organizationId">Novartis AG</TargetEntity></SourceEntity><SourceEntity id="24019" type="Company"><TargetEntity id="4295880493" type="organizationId">Banyu Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="27398" type="Company"><TargetEntity id="4297456613" type="organizationId">Kuhnil Pharm. Co Ltd</TargetEntity></SourceEntity><SourceEntity id="29723" type="Company"><TargetEntity id="5000332114" type="organizationId">Sepracor Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="29943" type="Company"><TargetEntity id="4296191056" type="organizationId">Medison Pharma Ltd</TargetEntity></SourceEntity><SourceEntity id="29954" type="Company"><TargetEntity id="4295891167" type="organizationId">TTY Biopharm Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1135" type="ciIndication"><TargetEntity id="M86" type="ICD10"></TargetEntity><TargetEntity id="730" type="ICD9"></TargetEntity><TargetEntity id="10031252" type="MEDDRA"></TargetEntity><TargetEntity id="D010019" type="MeSH"></TargetEntity><TargetEntity id="-1522277951" type="omicsDisease"></TargetEntity><TargetEntity id="2362" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="114" type="ciIndication"><TargetEntity id="10040047" type="MEDDRA"></TargetEntity><TargetEntity id="D018805" type="MeSH"></TargetEntity><TargetEntity id="-200243460" type="omicsDisease"></TargetEntity><TargetEntity id="953" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1267" type="ciIndication"><TargetEntity id="041.12" type="ICD9"></TargetEntity><TargetEntity id="813" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="138" type="ciIndication"><TargetEntity id="D016908" type="MeSH"></TargetEntity><TargetEntity id="-2050266020" type="omicsDisease"></TargetEntity><TargetEntity id="808" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1475" type="ciIndication"><TargetEntity id="A38" type="ICD10"></TargetEntity><TargetEntity id="034.1" type="ICD9"></TargetEntity></SourceEntity><SourceEntity id="1556" type="ciIndication"><TargetEntity id="10014666" type="MEDDRA"></TargetEntity><TargetEntity id="D004697" type="MeSH"></TargetEntity><TargetEntity id="-1617223493" type="omicsDisease"></TargetEntity><TargetEntity id="883" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1798" type="ciIndication"><TargetEntity id="10054088" type="MEDDRA"></TargetEntity></SourceEntity><SourceEntity id="1815" type="ciIndication"><TargetEntity id="J15" type="ICD10"></TargetEntity><TargetEntity id="10060946" type="MEDDRA"></TargetEntity><TargetEntity id="D018410" type="MeSH"></TargetEntity><TargetEntity id="-2031977293" type="omicsDisease"></TargetEntity><TargetEntity id="928" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="308" type="ciIndication"><TargetEntity id="4176" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="312" type="ciIndication"><TargetEntity id="10061372" type="MEDDRA"></TargetEntity><TargetEntity id="D013290" type="MeSH"></TargetEntity><TargetEntity id="-669221578" type="omicsDisease"></TargetEntity><TargetEntity id="814" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="40" type="ciIndication"><TargetEntity id="A49.9" type="ICD10"></TargetEntity><TargetEntity id="10060945" type="MEDDRA"></TargetEntity><TargetEntity id="D001424" type="MeSH"></TargetEntity><TargetEntity id="-1693440076" type="omicsDisease"></TargetEntity><TargetEntity id="800" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="485" type="ciIndication"><TargetEntity id="D017192" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="1594" type="Action"><TargetEntity id="4563" type="Mechanism">Anti-Diphteria Toxin (Corynebacterium diphtheriae)</TargetEntity><TargetEntity id="2409" type="Mechanism">Carbon Monoxide-Releasing Agents</TargetEntity><TargetEntity id="3878" type="Mechanism">Drugs Targeting Bacterial Chaperones</TargetEntity><TargetEntity id="5306" type="Mechanism">Drugs Targeting Mycobacterium tuberculosis Proteins</TargetEntity><TargetEntity id="3697" type="Mechanism">Drugs Targeting Escherichia coli Proteins</TargetEntity><TargetEntity id="4493" type="Mechanism">Drugs Targeting Campylobacter jejuni Proteins</TargetEntity><TargetEntity id="1060" type="Mechanism">Efflux Pump (Bacterial) Inhibitors</TargetEntity><TargetEntity id="3994" type="Mechanism">Drugs Targeting Pseudomonas aeruginosa Proteins</TargetEntity><TargetEntity id="4457" type="Mechanism">Drugs Targeting Staphylococcus aureus Proteins</TargetEntity><TargetEntity id="5053" type="Mechanism">Anti-Diphtheria Toxin</TargetEntity><TargetEntity id="5353" type="Mechanism">Drugs Targeting Clostridium tetani Proteins</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Bacterial skin infection - US - Nov-2003</FirstLaunched><FirstLaunched>Complicated skin and skin structure infection - US - Nov-2003</FirstLaunched><FirstLaunched>Enterococcus faecalis infection - US - Nov-2003</FirstLaunched><FirstLaunched>MRSA infection - US - Nov-2003</FirstLaunched><FirstLaunched>Staphylococcus aureus infection - US - Nov-2003</FirstLaunched><FirstLaunched>Streptococcus agalactiae infection - US - Nov-2003</FirstLaunched><FirstLaunched>Streptococcus infection - US - Nov-2003</FirstLaunched><FirstLaunched>Streptococcus pyogenes infection - US - Nov-2003</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="114">Sepsis</Indication><Indication id="1267">MRSA infection</Indication><Indication id="138">Gram positive bacterium infection</Indication><Indication id="1475">Streptococcus pyogenes infection</Indication><Indication id="1476">Streptococcus agalactiae infection</Indication><Indication id="1482">Enterococcus faecalis infection</Indication><Indication id="1556">Bacterial endocarditis</Indication><Indication id="308">Staphylococcus aureus infection</Indication><Indication id="312">Streptococcus infection</Indication><Indication id="3897">Complicated skin and skin structure infection</Indication><Indication id="40">Bacterial infection</Indication><Indication id="485">Bacterial skin infection</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1135">Osteomyelitis</Indication><Indication id="1798">Bacterial urinary tract infection</Indication><Indication id="1815">Bacterial pneumonia</Indication></IndicationsSecondary><ActionsSecondary><Action id="140">DNA synthesis inhibitor</Action><Action id="15187">Systemic dermatological antibacterial product</Action><Action id="1538">Bacterial protein synthesis inhibitor</Action><Action id="1594">Antibacterial</Action><Action id="439">RNA synthesis inhibitor</Action></ActionsSecondary><Technologies><Technology id="1647">Natural product</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="66">Antibiotic</Technology><Technology id="740">Infusion</Technology><Technology id="750">Freeze drying</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="80">Peptide</Technology><Technology id="898">Formulation powder</Technology></Technologies><EphmraCodes><Ephmra><Code>J1</Code><Name>SYSTEMIC ANTIBACTERIALS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-06-20T09:22:18.000Z</LastModificationDate><ChangeDateLast>2019-05-15T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="18077" linkType="Company"&gt;Merck &amp;amp; Co&lt;/ulink&gt; (following its acquisition of &lt;ulink linkID="21697" linkType="Company"&gt;Cubist Pharmaceuticals&lt;/ulink&gt;) and   licensees  &lt;ulink linkID="20268" linkType="Company"&gt;Sunovion&lt;/ulink&gt; and &lt;ulink linkID="14190" linkType="Company"&gt;AstraZeneca&lt;/ulink&gt;, under license from &lt;ulink linkID="17810" linkType="Company"&gt;Eli Lilly&lt;/ulink&gt;, have developed and launched  an iv infusion formulation of the cyclic lipopeptide antibiotic daptomycin (Cubicin; MK-3009; previously Cidecin) [&lt;ulink linkID="268910" linkType="Reference"&gt;268910&lt;/ulink&gt;], [&lt;ulink linkID="507496" linkType="Reference"&gt;507496&lt;/ulink&gt;], [&lt;ulink linkID="1627968" linkType="Reference"&gt;1627968&lt;/ulink&gt;] which binds to bacterial membranes, inducing a loss of membrane potential that disrupts processes such as RNA and protein synthesis. In the US, the drug is indicated for the treatment of the following infections: complicated skin and skin structure infections (cSSSI) caused by  susceptible isolates of Staphylococcus aureus (including methiciliin-resistant isolates; MRSA), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subspecies equisimilis, and Enterococcus faecalis (&lt;ulink linkID="44401" linkType="Drug"&gt;vancomycin&lt;/ulink&gt;-susceptible isolates only)  in adult and pediatric patients  (1 to 17 years of age); and bloodstream infections in adult and pediatric patients  (1 to 17 years of age), including infections with right-sided infective endocarditis (RIE; adults only), caused bymethicillin-susceptible S aureus (MSSA) and MRSA [&lt;ulink linkID="1130789" linkType="Reference"&gt;1130789&lt;/ulink&gt;]. In the EU, the drug is indicated for the treatment of complicated skin and soft tissue infections (cSSTI), RIE due to S aureus, and S aureus bacteremia when associated with  RIE or cSSTI [&lt;ulink linkID="1130968" linkType="Reference"&gt;1130968&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By November 2003, daptomycin had been launched in the US for cSSSI [&lt;ulink linkID="511436" linkType="Reference"&gt;511436&lt;/ulink&gt;]. In March 2006, Chiron launched the drug in the UK for cSSTI [&lt;ulink linkID="653868" linkType="Reference"&gt;653868&lt;/ulink&gt;]. By July 2006, it had also been launched in Germany and the Netherlands [&lt;ulink linkID="678795" linkType="Reference"&gt;678795&lt;/ulink&gt;]. In May 2006, the FDA approved the drug for S aureus bloodstream infections including RIE caused by MSSA and MRSA [&lt;ulink linkID="669778" linkType="Reference"&gt;669778&lt;/ulink&gt;], [&lt;ulink linkID="669840" linkType="Reference"&gt;669840&lt;/ulink&gt;]. In September 2007, daptomycin was approved for S aureus bacteremia and RIE in Europe [&lt;ulink linkID="828584" linkType="Reference"&gt;828584&lt;/ulink&gt;]; UK launch for these indications took place in September 2007 [&lt;ulink linkID="829842" linkType="Reference"&gt;829842&lt;/ulink&gt;]. In September 2011, the product was launched for the treatment of MRSA infection in Japan [&lt;ulink linkID="1224730" linkType="Reference"&gt;1224730&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2015, the EMA's CHMP recommended approval of daptomycin in pediatric patients aged 1 to 17 years with cSSTI in the EU [&lt;ulink linkID="1706157" linkType="Reference"&gt;1706157&lt;/ulink&gt;]; in April 2017, the EMA's CHMP requested additional information for the safety and efficacy aspects in the pediatric population with a specific timetable [&lt;ulink linkID="1947264" linkType="Reference"&gt;1947264&lt;/ulink&gt;]; in October 2017, the EMA's CHMP recommended EU approval of daptomycin for use in pediatric patients aged 1 to 17 years in the treatment of S aureus bacteremia associated with cSSTI [&lt;ulink linkID="1971227" linkType="Reference"&gt;1971227&lt;/ulink&gt;]. In March  and September 2017, the  product was approved in the US for  the  treatment of cSSSI and S aureus bacteremia, respectively, in pediatric patients aged 1 to 17 years [&lt;ulink linkID="2049871" linkType="Reference"&gt;2049871&lt;/ulink&gt;], [&lt;ulink linkID="2049871" linkType="Reference"&gt;2049871&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2009, Novartis launched a 2-min rapid injection formulation of daptomycin in the EU [&lt;ulink linkID="1085727" linkType="Reference"&gt;1085727&lt;/ulink&gt;]. In December 2010, the FDA approved daptomycin for qd dosing as a 2-min iv injection for MRSA, cSSSI and bacteremia [&lt;ulink linkID="1153128" linkType="Reference"&gt;1153128&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Cubist was previously developing the drug for the potential treatment of community-acquired pneumonia (CAP) and  complicated urinary tract infections (cUTI)  [&lt;ulink linkID="439841" linkType="Reference"&gt;439841&lt;/ulink&gt;], [&lt;ulink linkID="393026" linkType="Reference"&gt;393026&lt;/ulink&gt;]; however, no development has been reported for these indications.    In January 2014, a phase III trial for osteomyelitis was initiated, and in December 2016, the  trial was completed [&lt;ulink linkID="1469277" linkType="Reference"&gt;1469277&lt;/ulink&gt;]; no development has since been reported. &lt;/para&gt;&lt;para&gt;An &lt;ulink linkID="35444" linkType="Drug"&gt;oral formulation&lt;/ulink&gt; was also under investigation by Cubist [&lt;ulink linkID="417019" linkType="Reference"&gt;417019&lt;/ulink&gt;]; however, development was discontinued in March 2003 [&lt;ulink linkID="503970" linkType="Reference"&gt;503970&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;By December 2002, the primary composition of matter patent for daptomycin had expired [&lt;ulink linkID="503970" linkType="Reference"&gt;503970&lt;/ulink&gt;]. By January 2011, five US patents had been issued covering the  product, its manufacture, and its administration and use, including &lt;ulink linkID="IN2692673" linkType="Patent"&gt;&lt;/ulink&gt;&lt;ulink linkID="PA2911737" linkType="Patent"&gt;US-06852689&lt;/ulink&gt;, &lt;ulink linkID="PA3025563" linkType="Patent"&gt;US-06696412&lt;/ulink&gt;, &lt;ulink linkID="PA2903761" linkType="Patent"&gt;US-6468967&lt;/ulink&gt;, US-RE39071 and &lt;ulink linkID="IN1477268" linkType="Patent"&gt;US-04885243&lt;/ulink&gt;, which were due to expire on September 2019, November 2020, September 2019, June 2016 and December 2011, respectively [&lt;ulink linkID="1172820" linkType="Reference"&gt;1172820&lt;/ulink&gt;]. The FDA also granted daptomycin 5 years NCE exclusivity under the Hatch-Waxman act, which expired in September 2008 [&lt;ulink linkID="592039" linkType="Reference"&gt;592039&lt;/ulink&gt;]. By January 2011, a patent term extension in the US had been applied to &lt;ulink linkID="IN1477268" linkType="Patent"&gt;US-04885243&lt;/ulink&gt; [&lt;ulink linkID="1172820" linkType="Reference"&gt;1172820&lt;/ulink&gt;]. By February 2012, Cubist had also been granted two additional US patents, &lt;ulink linkID="PA5450990" linkType="Patent"&gt;US-08003673&lt;/ulink&gt; and &lt;ulink linkID="PA3535313" linkType="Patent"&gt;US-08058238&lt;/ulink&gt;, covering daptomycin, which expire on September 04, 2028, and November 28, 2020, respectively; &lt;ulink linkID="IN1477268" linkType="Patent"&gt;US-04885243&lt;/ulink&gt; had expired. By that time,     Cubist was working with the FDA to obtain pediatric exclusivity for daptomycin [&lt;ulink linkID="1261530" linkType="Reference"&gt;1261530&lt;/ulink&gt;], [&lt;ulink linkID="1268989" linkType="Reference"&gt;1268989&lt;/ulink&gt;]; in February 2013, Cubist was still working with the FDA to obtain pediatric exclusivity [&lt;ulink linkID="1392842" linkType="Reference"&gt;1392842&lt;/ulink&gt;].  At that time, Cubist stated that another issued US patent, &lt;ulink linkID="PA6550089" linkType="Patent"&gt;US-08129342&lt;/ulink&gt;, was due to expire in November 2020 [&lt;ulink linkID="1392842" linkType="Reference"&gt;1392842&lt;/ulink&gt;]. In February 2014, Cubist stated that it had additional patents related to the composition, manufacture and/or use of the product in Europe; the last of these was to expire in January 2021 [&lt;ulink linkID="1529582" linkType="Reference"&gt;1529582&lt;/ulink&gt;]. In January 2015, Novartis noted that data exclusivity would expire in the EU in 2016 [&lt;ulink linkID="1636427" linkType="Reference"&gt;1636427&lt;/ulink&gt;]. In February 2018, Merck expected loss of market exclusivity in some European markets in early 2018 [&lt;ulink linkID="2010325" linkType="Reference"&gt;2010325&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2007, Cubist announced an error in one of the daptomycin patents (US-RE39071) listed in the Orange Book; the stereochemistry of an amino acid was incorrectly identified. Cubist requested that the FDA de-list the composition patent and the company was to pursue the appropriate course of action with the USPTO to correct the error [&lt;ulink linkID="829727" linkType="Reference"&gt;829727&lt;/ulink&gt;]. In February 2008, the FDA received the relisting application for US-RE39071; Cubist expected the FDA to publish the relisted patent in the next Orange Book update [&lt;ulink linkID="874574" linkType="Reference"&gt;874574&lt;/ulink&gt;].  The US-RE39071 composition of matter patent expired in June 2016 [&lt;ulink linkID="1904530" linkType="Reference"&gt;1904530&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2009, &lt;ulink linkID="20348" linkType="Company"&gt;Teva&lt;/ulink&gt; filed an ANDA with the FDA for generic daptomycin, prior to the expiration of &lt;ulink linkID="PA2903761" linkType="Patent"&gt;US-06468967&lt;/ulink&gt;, &lt;ulink linkID="PA2911737" linkType="Patent"&gt;US-06852689&lt;/ulink&gt; and US-RE39071 [&lt;ulink linkID="982926" linkType="Reference"&gt;982926&lt;/ulink&gt;]. In March 2009, Cubist filed a patent infringement lawsuit against Teva  [&lt;ulink linkID="994184" linkType="Reference"&gt;994184&lt;/ulink&gt;]. At that time, the court also scheduled a claim construction (Markman) hearing for June 2010 [&lt;ulink linkID="1063860" linkType="Reference"&gt;1063860&lt;/ulink&gt;]. In June 2010, the Markman hearing was cancelled [&lt;ulink linkID="1106009" linkType="Reference"&gt;1106009&lt;/ulink&gt;]; the district court issued a  claim construction order later that month [&lt;ulink linkID="1106555" linkType="Reference"&gt;1106555&lt;/ulink&gt;]. Also in June 2010, Cubist announced that it would oppose Teva's motion to amend its answer alleging that the '967 and '689 patents are unenforceable due to inequitable conduct [&lt;ulink linkID="1107577" linkType="Reference"&gt;1107577&lt;/ulink&gt;]. In September 2010, Teva's motion for leave to amend was accepted, and Teva filed its amendment alleging that the '967 and '689 patents were due to inequitable conduct. In October 2010, a Stipulation and Proposed Order was filed regarding the infringement; Teva agreed that the proposed labelling would infringe the claims of the '967 and '689 patents. However, Teva maintained that the claims were invalid and unenforceable. Also that month, the court signed the infringement stipulation [&lt;ulink linkID="1172820" linkType="Reference"&gt;1172820&lt;/ulink&gt;]. In November 2010, Cubist filed a Citizen Petition with the FDA, requesting the non-approval of ANDAs for generic daptomycin until ANDA applicants had met specific conditions related to bioequivalence,  manufacturing quality controls and  safety [&lt;ulink linkID="1154113" linkType="Reference"&gt;1154113&lt;/ulink&gt;], [&lt;ulink linkID="1172820" linkType="Reference"&gt;1172820&lt;/ulink&gt;].  In April 2011, Teva and Cubist settled the ongoing litigation; under the terms of the agreement, Teva is permitted to launch its generic in the US on June 24, 2018 if Cubist obtains 6-month  marketing exclusivity extension, or otherwise on December 24, 2017. Teva also agreed to  buy daptomycin exclusively from Cubist. Teva admitted that the patents asserted in the lawsuit were valid,  enforceable against and would be infringed by Teva's proposed generic [&lt;ulink linkID="1181558" linkType="Reference"&gt;1181558&lt;/ulink&gt;]. In February 2014, Cubist noted that the license granted to Teva would expire upon the expiry of all licensed patents, including any pediatric or other exclusivity [&lt;ulink linkID="1529582" linkType="Reference"&gt;1529582&lt;/ulink&gt;]. In February 2015, Merck noted that if the &lt;ulink linkID="1010293" linkType="Company"&gt;Hospira&lt;/ulink&gt; decision was upheld on appeal, Teva would be permitted to launch in June 2016 [&lt;ulink linkID="1642667" linkType="Reference"&gt;1642667&lt;/ulink&gt;]. In November 2015, the US Court of Appeals for the Federal Circuit validated the patent for daptomycin, which expires in June 2016, but invalidated four patents with expiration dates in 2019 and 2020. At that time, Merck was reviewing the ruling to determine the next steps forward [&lt;ulink linkID="1713208" linkType="Reference"&gt;1713208&lt;/ulink&gt;]. By May 2016, Cubist had appealed the November 2015 decision. At that time, the US Supreme Court rejected Cubist's patent appeal upholding   the invalidity of the four patents expiring between 2019 and 2020  [&lt;ulink linkID="1767722" linkType="Reference"&gt;1767722&lt;/ulink&gt;]. In September 2016, Teva launched its authorized generic version of daptomycin injection (500 mg) in the US for cSSSI [&lt;ulink linkID="1796728" linkType="Reference"&gt;1796728&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2012, Hospira filed an ANDA containing a Paragraph IV certification for its generic daptomycin (500 mg)  injection product, seeking to launch its product prior to expiry of the Orange Book-listed patents &lt;ulink linkID="PA2903761" linkType="Patent"&gt;US-06468967&lt;/ulink&gt;, &lt;ulink linkID="PA2911737" linkType="Patent"&gt;US-06852689&lt;/ulink&gt;, US-RE39071, &lt;ulink linkID="PA3535313" linkType="Patent"&gt;US-08058238&lt;/ulink&gt; and &lt;ulink linkID="PA5450990" linkType="Patent"&gt;US-08003673&lt;/ulink&gt; [&lt;ulink linkID="1261530" linkType="Reference"&gt;1261530&lt;/ulink&gt;], [&lt;ulink linkID="1268989" linkType="Reference"&gt;1268989&lt;/ulink&gt;]. In March 2012, Cubist filed a lawsuit alleging patent infringement. In May 2012, Hospira submitted an amended ANDA containing a Paragraph IV certification  seeking approval of generic daptomycin (500 mg) prior to expiry of &lt;ulink linkID="PA6550089" linkType="Patent"&gt;US-08129342&lt;/ulink&gt;, and in July 2012, Cubist filed a complaint. In August 2012, Cubist received a third Paragraph IV certification notice letter from Hospira following submission of a filing seeking approval of generic daptomycin (350 mg) prior to expiry of &lt;ulink linkID="PA2903761" linkType="Patent"&gt;US-06468967&lt;/ulink&gt;, &lt;ulink linkID="PA2911737" linkType="Patent"&gt;US-06852689&lt;/ulink&gt;, US-RE39071, &lt;ulink linkID="PA3535313" linkType="Patent"&gt;US-08058238&lt;/ulink&gt; and &lt;ulink linkID="PA6550089" linkType="Patent"&gt;US-08129342&lt;/ulink&gt;; in September 2012, Cubist filed a patent infringement complaint against Hospira in response to its filing; the complaint aimed to prevent the effective date of FDA approval of Hospira's filings until patent expiry and should result in a 30-month stay from Cubist's first lawsuit filing. In February 2013, Cubist stated that  a trial date was scheduled beginning February 18, 2014, and a Markman hearing was to take place on April 10, 2013 [&lt;ulink linkID="1392842" linkType="Reference"&gt;1392842&lt;/ulink&gt;]. In March 2013, Hospira was granted tentative FDA approval for its generic version of daptomycin injection (350 mg) [&lt;ulink linkID="1393383" linkType="Reference"&gt;1393383&lt;/ulink&gt;]. In July 2013, the court endorsed the stipulation that Hospira's ANDA infringed certain claims in the asserted patents. In February 2014, the patent infringement lawsuit against Hospira began [&lt;ulink linkID="1529582" linkType="Reference"&gt;1529582&lt;/ulink&gt;]. In December 2014, a US District Court ruled against Hospira on the re-issue patent US-RE39071; the ruling would prohibit Hospira from entering the market until June 15, 2016. At that time, the US District Court had ruled against Cubist on US-06468967, US-06852689, US-08058238 and US-08129342 [&lt;ulink linkID="1619289" linkType="Reference"&gt;1619289&lt;/ulink&gt;]; by February 2015, Cubist had appealed the Court's judgement on the later patents, and Hospira had appealed the Court's decision on the validity of the composition patent US-RE39071. At that time, Merck noted that if the decision was upheld on appeal,  Hospira's ANDA submission would not be approved until at least June 2016  [&lt;ulink linkID="1642667" linkType="Reference"&gt;1642667&lt;/ulink&gt;]. In November 2015, the US Court of Appeals for the Federal Circuit affirmed the lower court decision validating the patent for daptomycin, which expires in June 2016, but invalidating the four patents with expiration dates in 2019 and 2020. At that time, Merck was reviewing the ruling to determine the next steps forward [&lt;ulink linkID="1713208" linkType="Reference"&gt;1713208&lt;/ulink&gt;], [&lt;ulink linkID="1743025" linkType="Reference"&gt;1743025&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2013, &lt;ulink linkID="1006172" linkType="Company"&gt;Strides&lt;/ulink&gt;, on behalf of &lt;ulink linkID="1072180" linkType="Company"&gt;Agila Specialities&lt;/ulink&gt;, filed an ANDA containing a Paragraph IV certification for its generic daptomycin (500 mg)  injection product, seeking to launch its product prior to expiry of the Orange Book-listed patents &lt;ulink linkID="PA2903761" linkType="Patent"&gt;US-06468967&lt;/ulink&gt;, &lt;ulink linkID="PA2911737" linkType="Patent"&gt;US-06852689&lt;/ulink&gt;, &lt;ulink linkID="PA3535313" linkType="Patent"&gt;US-08058238&lt;/ulink&gt;, &lt;ulink linkID="PA5450990" linkType="Patent"&gt;&lt;/ulink&gt;&lt;ulink linkID="PA6550089" linkType="Patent"&gt;US-08129342&lt;/ulink&gt; and &lt;ulink linkID="PA5450990" linkType="Patent"&gt;US-08003673&lt;/ulink&gt;, and stating that the claims in the patents were invalid, and/or unenforcable and/or would not be infringed by Strides' product. In October 2013, Cubist filed two patent infringement lawsuits in different District Courts against Strides. Cubist later filed a notice of dismissal in one of the courts and the case was terminated; the complaint in  the other court alleges infringement of US-06468967, US-06852689, US-08058238 and US-08129342, and aimed to  prevent the effective date of FDA approval of Strides' filing until expiration of the patents and should result in a 30-month stay from Cubist's first lawsuit filing [&lt;ulink linkID="1529582" linkType="Reference"&gt;1529582&lt;/ulink&gt;]. In October 2014, Agila and Mylan filed petitions 	for Inter Partes Review (IPR) at the USPTO seeking the invalidity of the September 2019 and November 2020 patents [&lt;ulink linkID="1743025" linkType="Reference"&gt;1743025&lt;/ulink&gt;]. In February 2015, Merck noted that if the Hospira decision was upheld on appeal, Strides' ANDA would not be approved until at least June 2016 [&lt;ulink linkID="1642667" linkType="Reference"&gt;1642667&lt;/ulink&gt;]. In April 2015, Agila and Mylan withdrew the petitions for IPR in exchange for Merck agreeing to narrow the issues in the Strides and Agila lawsuit [&lt;ulink linkID="1743025" linkType="Reference"&gt;1743025&lt;/ulink&gt;]. In November 2015, the US Court of Appeals for the Federal Circuit validated the patent for daptomycin, which expires in June 2016, but invalidated four patents with expiration dates in 2019 and 2020. At that time, Merck was reviewing the ruling to determine the next steps forward [&lt;ulink linkID="1713208" linkType="Reference"&gt;1713208&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2014, &lt;ulink linkID="27814" linkType="Company"&gt;Fresenius&lt;/ulink&gt; had filed an ANDA for its generic version of daptomycin. At that time, a patent infringement lawsuit was filed in the US against Fresenius [&lt;ulink linkID="1642667" linkType="Reference"&gt;1642667&lt;/ulink&gt;]. In November 2014, Fresenius filed petitions for IPR at the USPTO seeking the invalidity of the September 2019 patents [&lt;ulink linkID="1743025" linkType="Reference"&gt;1743025&lt;/ulink&gt;]. In February 2015, Merck stated that the lawsuit stayed FDA approval of Fresenius' ANDA submission until November 2016 or until an adverse Court's decision, if any, whichever may occur earlier. At that time, the company also noted that if the Hospira decision was upheld on appeal, Fresenius' ANDA would not be approved until at least June 2016 [&lt;ulink linkID="1642667" linkType="Reference"&gt;1642667&lt;/ulink&gt;]. In May 2015, Fresenius' petition for an IPR on the September 2019 patents was granted. In July 2015, Fresenius filed petitions for IPR seeking invalidity of the November 2020 patents [&lt;ulink linkID="1743025" linkType="Reference"&gt;1743025&lt;/ulink&gt;]. In November 2015, the US Court of Appeals for the Federal Circuit validated the patent for daptomycin, which expires in June 2016, but invalidated four patents with expiration dates in 2019 and 2020. At that time, Merck was reviewing the ruling to determine the next steps forward [&lt;ulink linkID="1713208" linkType="Reference"&gt;1713208&lt;/ulink&gt;]. In January 2016, the USPTO granted Fresenius’s petition for an IPR on the November 2020 patents. In February 2016, the IPR hearing on the September 2019 patents was held [&lt;ulink linkID="1743025" linkType="Reference"&gt;1743025&lt;/ulink&gt;]. In September 2016, Fresenius launched its  generic daptomycin  injection in the US [&lt;ulink linkID="1798029" linkType="Reference"&gt;1798029&lt;/ulink&gt;].  In April 2018, the FDA approved Fresenius's 500 mg strength generic version of daptomycin for injection, which was immediately launched in the US [&lt;ulink linkID="2023339" linkType="Reference"&gt;2023339&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2015, &lt;ulink linkID="1034907" linkType="Company"&gt;Sagent Pharmaceuticals&lt;/ulink&gt; had filed an ANDA for its generic version of daptomycin. At that time, a patent infringement lawsuit was filed in the US against Sagent. As a result of the Hospira decision, Sagent’s ANDA would not be approved until at least June 2016 [&lt;ulink linkID="1743025" linkType="Reference"&gt;1743025&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Also by December 2015, &lt;ulink linkID="1047780" linkType="Company"&gt;Actavis&lt;/ulink&gt; had filed an ANDA for its generic version of daptomycin. At that time, a patent infringement lawsuit was filed in the US against Actavis. As a result of the Hospira decision, Actavis' ANDA would not be approved until at least June 2016 [&lt;ulink linkID="1743025" linkType="Reference"&gt;1743025&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By January 2016, &lt;ulink linkID="29387" linkType="Company"&gt;Dr Reddy's Laboratories&lt;/ulink&gt; had filed an ANDA for its generic version of daptomycin. At that time, a patent infringement lawsuit was filed in the US against Reddy's. As a result of the Hospira decision, Reddy’s ANDA would not be approved until at least June 2016 [&lt;ulink linkID="1743025" linkType="Reference"&gt;1743025&lt;/ulink&gt;]. By May 2019, the ANDA had been approved; at that time, Dr Reddy's launched its generic version of the drug (500 mg / 15 ml, single dose vial) in the US [&lt;ulink linkID="2151764" linkType="Reference"&gt;2151764&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;In November 2018, &lt;ulink linkID="1057904" linkType="Company"&gt;Chengdu Yacht Biotechnology&lt;/ulink&gt; filed an ANDA for its generic version of daptomycin in China [&lt;ulink linkID="2089040" linkType="Reference"&gt;2089040&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2019, &lt;ulink linkID="1067800" linkType="Company"&gt;AnShi Pharmaceutical &lt;/ulink&gt;filed an an ANDA for its generic version of daptomycin in China [&lt;ulink linkID="2115841" linkType="Reference"&gt;2115841&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;&lt;subtitle&gt;Community-acquired pneumonia&lt;/subtitle&gt;In 1999, daptomycin was given Fast Track status by the FDA [&lt;ulink linkID="337556" linkType="Reference"&gt;337556&lt;/ulink&gt;]. In July 2001, Cubist was planning an NDA filing for cSSTI and community-acquired pneumonia (CAP), both with and without associated bacteremia, and planned to include data on treating resistant infections, including vancomycin-resistant enterococci (VRE), MRSA and penicillin-resistant S pneumoniae (PRSP) [&lt;ulink linkID="415799" linkType="Reference"&gt;415799&lt;/ulink&gt;]. As of January 2002, Cubist  still planned to pursue initial indications for CAP [&lt;ulink linkID="436186" linkType="Reference"&gt;436186&lt;/ulink&gt;]. However, later in January 2002, following preliminary phase III trial results, Cubist announced that it was re-evaluating its options regarding the CAP indication  [&lt;ulink linkID="436210" linkType="Reference"&gt;436210&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Complicated skin and skin structure infections&lt;/subtitle&gt;In June  2016, an sNDA was filed in the US for the potential treatment of cSSSI in pediatric patients aged 1 to 17 years. In March 2017, the  product was approved in this setting [&lt;ulink linkID="2049871" linkType="Reference"&gt;2049871&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2010, the FDA approved daptomycin for qd dosing as a 2-min iv injection for cSSSI [&lt;ulink linkID="1153128" linkType="Reference"&gt;1153128&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2002, an NDA was filed for the potential treatment of cSSSI caused by Gram-positive organisms, including both susceptible and resistant strains of S aureus [&lt;ulink linkID="474813" linkType="Reference"&gt;474813&lt;/ulink&gt;]. In February 2003, the FDA accepted the NDA and granted daptomycin Priority Review status [&lt;ulink linkID="479414" linkType="Reference"&gt;479414&lt;/ulink&gt;]. In September 2003, daptomycin was approved for the treatment of cSSSI caused by susceptible strains of the following Gram-positive microorganisms: S aureus (including methicillin-resistant strains), S pyogenes, S agalactiae, S dysgalactiae subsp equisimilis and E faecalis (vancomycin-susceptible strains only);  US launch took place in November 2003 [&lt;ulink linkID="504729" linkType="Reference"&gt;504729&lt;/ulink&gt;], [&lt;ulink linkID="511436" linkType="Reference"&gt;511436&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Endocarditis and bacteremia&lt;/subtitle&gt;In March 2017, an sNDA was filed in the US for the potential treatment of S aureus bacteremia in pediatric patients aged 1 to 17 years. In September 2017, the  product was approved in this setting [&lt;ulink linkID="2049871" linkType="Reference"&gt;2049871&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2010, the FDA approved daptomycin for qd dosing as a 2-min iv injection for MRSA and bacteremia [&lt;ulink linkID="1153128" linkType="Reference"&gt;1153128&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2005, Cubist submitted an sNDA to the FDA for use of the drug in patients with bacteremia with known or suspected endocarditis caused by S aureus [&lt;ulink linkID="625104" linkType="Reference"&gt;625104&lt;/ulink&gt;]. The FDA accepted the application in November 2005 and granted it a Priority Review  [&lt;ulink linkID="636218" linkType="Reference"&gt;636218&lt;/ulink&gt;]. In March 2006, the FDA's Anti-Infective Drugs Advisory Committee voted that daptomycin was safe and effective for treating S aureus bacteremia and infective carditis [&lt;ulink linkID="654416" linkType="Reference"&gt;654416&lt;/ulink&gt;]. Later that month, the company received an approvable letter from the FDA requiring agreement on the label for the drug [&lt;ulink linkID="657899" linkType="Reference"&gt;657899&lt;/ulink&gt;]; Cubist submitted an amendment to the sNDA in response to the approvable letter later that month [&lt;ulink linkID="658174" linkType="Reference"&gt;658174&lt;/ulink&gt;]. In May 2006, the FDA approved daptomycin for the treatment of S aureus bloodstream infections, including RIE caused by MSSA and MRSA [&lt;ulink linkID="669778" linkType="Reference"&gt;669778&lt;/ulink&gt;], [&lt;ulink linkID="669840" linkType="Reference"&gt;669840&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;&lt;subtitle&gt;Complicated skin and soft tissue infections&lt;/subtitle&gt;In December 2004, Chiron submitted an MAA to the EMA for cSSTI caused by Gram-positive bacteria [&lt;ulink linkID="574069" linkType="Reference"&gt;574069&lt;/ulink&gt;]. In November 2005, the EMA's CHMP recommended approval of the MAA and approval was granted in January 2006 for the EU, Iceland, Liechtenstein, France, Estonia,  Norway, Lithuania and Slovakia   [&lt;ulink linkID="635614" linkType="Reference"&gt;635614&lt;/ulink&gt;], [&lt;ulink linkID="646449" linkType="Reference"&gt;646449&lt;/ulink&gt;],    [&lt;ulink linkID="1348829" linkType="Reference"&gt;1348829&lt;/ulink&gt;], [&lt;ulink linkID="1459778" linkType="Reference"&gt;1459778&lt;/ulink&gt;], [&lt;ulink linkID="1464029" linkType="Reference"&gt;1464029&lt;/ulink&gt;], [&lt;ulink linkID="1467794" linkType="Reference"&gt;1467794&lt;/ulink&gt;]  and later the drug was launched in Iceland [&lt;ulink linkID="1450511" linkType="Reference"&gt;1450511&lt;/ulink&gt;]. In March 2006, it was launched in the UK [&lt;ulink linkID="653868" linkType="Reference"&gt;653868&lt;/ulink&gt;]; at that time the drug was approved in Spain for  cSSSI; by January 2013, the drug had been launched  [&lt;ulink linkID="1357111" linkType="Reference"&gt;1357111&lt;/ulink&gt;]. By July 2006, it had also been launched in Germany and the Netherlands [&lt;ulink linkID="678795" linkType="Reference"&gt;678795&lt;/ulink&gt;]. In November 2006, the drug was launched in Denmark [&lt;ulink linkID="1422826" linkType="Reference"&gt;1422826&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2015, the EMA's CHMP adopted a positive opinion for the approval of daptomycin in pediatric patients aged 1 to 17 years with cSSTI in the EU [&lt;ulink linkID="1706157" linkType="Reference"&gt;1706157&lt;/ulink&gt;]. In April 2017, the EMA's CHMP requested additional information for the safety and efficacy aspects in the pediatric population with a specific timetable [&lt;ulink linkID="1947264" linkType="Reference"&gt;1947264&lt;/ulink&gt;]; in October 2017, the EMA's CHMP recommended approval of daptomycin for use in pediatric patients aged 1 to 17 years in the treatment of S aureus bacteremia associated with cSSTI [&lt;ulink linkID="1971227" linkType="Reference"&gt;1971227&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Endocarditis and bacteremia&lt;/subtitle&gt;In January 2006, the product was approved in France and was launched   in March 2007   [&lt;ulink linkID="1348829" linkType="Reference"&gt;1348829&lt;/ulink&gt;]; at that time, the drug was approved in Slovakia [&lt;ulink linkID="1467794" linkType="Reference"&gt;1467794&lt;/ulink&gt;].  In July 2007, the CHMP recommended approval for the extension of the indication to include treatment of RIE, and in September 2007 the drug was approved for the indication, as well as for S aureus bacteremia when associated with RIE or with cSSTI [&lt;ulink linkID="816072" linkType="Reference"&gt;816072&lt;/ulink&gt;], [&lt;ulink linkID="828584" linkType="Reference"&gt;828584&lt;/ulink&gt;]. In September 2007, daptomycin was launched in the UK for S bacteremia and RIE [&lt;ulink linkID="829842" linkType="Reference"&gt;829842&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2009, Novartis launched a 2-minute rapid injection formulation of daptomycin in the EU [&lt;ulink linkID="1085727" linkType="Reference"&gt;1085727&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;By September 2010, Japanese licensee Merck &amp;amp; Co (via its subsidiary &lt;ulink linkID="24019" linkType="Company"&gt;MSD Japan&lt;/ulink&gt;, formerly Banyu Pharmaceutical) had filed for approval  for MRSA infection  [&lt;ulink linkID="1134864" linkType="Reference"&gt;1134864&lt;/ulink&gt;]. In July 2011, the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the drug for the treatment of MRSA infections [&lt;ulink linkID="1204912" linkType="Reference"&gt;1204912&lt;/ulink&gt;]; the product was launched in September 2011 [&lt;ulink linkID="1224730" linkType="Reference"&gt;1224730&lt;/ulink&gt;]. In July 2013, an additional dosage was reported to the Pharmaceutical and Affairs Food Sanitation Council's Second Committee on Drugs [&lt;ulink linkID="1466733" linkType="Reference"&gt;1466733&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;&lt;subtitle&gt;Complicated skin and soft tissue infections&lt;/subtitle&gt;In September 2012, licensee AstraZeneca submitted a regulatory filing in China for cSSSI [&lt;ulink linkID="1396542" linkType="Reference"&gt;1396542&lt;/ulink&gt;]; however, since that time, no further development has been reported. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Endocarditis and bacteremia&lt;/subtitle&gt;By October  2009, the drug was approved in China for bloodstream infection;  however, before launch could take place, AstraZeneca was required to obtain additional distribution and pricing approval. At that time, launch was stated for 2H10 [&lt;ulink linkID="1050030" linkType="Reference"&gt;1050030&lt;/ulink&gt;]. By May 2012, the drug had been launched in China by AstraZeneca [&lt;ulink linkID="1286096" linkType="Reference"&gt;1286096&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;&lt;subtitle&gt;Complicated skin and soft tissue infections&lt;/subtitle&gt;In September 2007, the drug was approved in Canada for cSSSI and bloodstream infections, including RIE [&lt;ulink linkID="833172" linkType="Reference"&gt;833172&lt;/ulink&gt;]; the product was launched in December 2007 [&lt;ulink linkID="1130846" linkType="Reference"&gt;1130846&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;&lt;subtitle&gt;Complicated skin and soft tissue infections&lt;/subtitle&gt;By April 2012, the drug had been launched in Chile [&lt;ulink linkID="1351928" linkType="Reference"&gt;1351928&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By January 2013, the drug was approved as Cubicin in Brazil [&lt;ulink linkID="1647989" linkType="Reference"&gt;1647989&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Middle East and Africa&lt;/subtitle&gt;&lt;subtitle&gt;Complicated skin and soft tissue infections&lt;/subtitle&gt;By September 2010, daptomycin had been approved in Israel for cSSSI [&lt;ulink linkID="1130971" linkType="Reference"&gt;1130971&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Endocarditis and bacteramia&lt;/subtitle&gt;By September 2010, daptomycin had been approved in Israel for bacteremia and RIE [&lt;ulink linkID="1130971" linkType="Reference"&gt;1130971&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;&lt;subtitle&gt;Complicated skin and soft tissue infections&lt;/subtitle&gt;In November 2006, daptomycin  was approved in Taiwan for cSSSI caused by Gram-positive bacteria [&lt;ulink linkID="817990" linkType="Reference"&gt;817990&lt;/ulink&gt;]; by May 2014, the drug had been launched there as Cubicin [&lt;ulink linkID="1721188" linkType="Reference"&gt;1721188&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2007, the drug was approved for cSSSI in South Korea [&lt;ulink linkID="817990" linkType="Reference"&gt;817990&lt;/ulink&gt;]. It was made available there in December 2010  [&lt;ulink linkID="1578005" linkType="Reference"&gt;1578005&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2009, daptomycin had been approved in Australia for cSSSI [&lt;ulink linkID="1130851" linkType="Reference"&gt;1130851&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Endocarditis and bacteremia&lt;/subtitle&gt;In August 2007, the drug was approved in Taiwan  for S aureus bacteremia  [&lt;ulink linkID="817990" linkType="Reference"&gt;817990&lt;/ulink&gt;]; by May 2014, the drug had been launched there as Cubicin [&lt;ulink linkID="1721188" linkType="Reference"&gt;1721188&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2007, the drug was approved in South Korea for S aureus bacteremia  [&lt;ulink linkID="817990" linkType="Reference"&gt;817990&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2009, daptomycin had been approved in Australia for bacteremia and RIE caused by S  aureus [&lt;ulink linkID="1130851" linkType="Reference"&gt;1130851&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;SAFETY INFORMATION&lt;/subtitle&gt;In July 2010, the FDA issued a safety communication regarding the risk of eosinophilic pneumonia associated with daptomycin, following a review of published case reports and postmarketing adverse event reports. At that time, the FDA requested that Cubist amend the drug's label to include the information [&lt;ulink linkID="1120163" linkType="Reference"&gt;1120163&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;In August 2011, a phase IV, randomized, open-label, parallel-group study (&lt;ulink linkID="80151" linkType="Protocol"&gt;NCT01419184&lt;/ulink&gt;; DAP-HEOR-1006) was initiated in the US, to compare daptomycin (4 mg/kg) versus vancomycin on patient (estimated n = 250) and health outcomes including; infection-related hospital length of stay, pain symptoms and health-related quality of life, cSSSI-related hospital readmission rates, medical resource utilization and costs. Enrollment was ongoing in December 2011, and the study was expected to complete in January 2013 [&lt;ulink linkID="1251751" linkType="Reference"&gt;1251751&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In July 2008, a prospective, open-label pharmacokinetic, phase III study (&lt;ulink linkID="186562" linkType="Protocol"&gt;NCT00701636&lt;/ulink&gt;; 12903-01 IIS 0003-07-2007) was initiated  in the US in patients (estimated n = 30) undergoing coronary artery by pass graft surgery without valvular replacement; including late effects of surgery, Staphylococcus Aureus, surgical site infection. The study was completed by October 2010 [&lt;ulink linkID="1871925" linkType="Reference"&gt;1871925&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In May 2011, clinical data were presented at the 21st ECCMID/27th ICC in Milan, Italy. Results from a non-interventional trial in patients (n = 2041) with gram-positive baterial infections showed that clinical success rates for daptomycin were 82, 85, 78, 72 and 81% for MSSA, MRSA, coagulase-negative Staphylococci, Enterococcus faecalis and Enterococcus faecium, respectively. The drug was well tolerated and serious adverse events were reported in 7% of patients [&lt;ulink linkID="1218126" linkType="Reference"&gt;1218126&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2011, data were published from the EU-CORE study, which assessed the real-world efficacy of daptomycin. The overall clinical success rate was 79%; low failure rates were observed regardless of whether daptomycin was used as a first- or second-line therapy (6 and 8%, respectively) [&lt;ulink linkID="1305889" linkType="Reference"&gt;1305889&lt;/ulink&gt;]. In May 2011, further data were presented at the 21st ECCMID/27th ICC in Milan, Italy. An analysis of the EU-CORE study evaluated the safety and tolerability of daptomycin in patients (n = 270) with Gram-positive bacterial infections. The overall clinical success rate for a &amp;gt;/= 8 mg/kg dose was 80%. Adverse events and serious adverse events were similar between groups receiving &amp;gt;/= or &amp;lt; 8 mg/kg doses [&lt;ulink linkID="1217647" linkType="Reference"&gt;1217647&lt;/ulink&gt;]. Futher data evaluated  safety in patients receiving hemodialysis. Success rates with daptomycin were 82 and 65% against bacteremia, and skin and soft tissue infection, respectively, and in patients with confirmed pathogens, the clinical success rates for S aureus and coagulase-negative Staphylococci were 75 and 78%, respectively [&lt;ulink linkID="1217648" linkType="Reference"&gt;1217648&lt;/ulink&gt;]. In April 2015, further clinical data in 6075 patients were presented at the 25th ECCMID in Copenhagen, Denmark. Sustained response was observed in the majority of patients with endocarditis or osteomyelitis/orthopedic device infection and no new or unexpected safety findings were reported [&lt;ulink linkID="1653440" linkType="Reference"&gt;1653440&lt;/ulink&gt;]. Further clinical data  from 432 osteomyelitis patients   were also presented at the same conference showing that daptomycin  was effective with an overall clinical success rate of 80% and was well tolerated in patients with osteomyelitis caused by gram-positive bacteria, both non-prosthetic and prosthetic device-related osteomyelitis. A sustained response was observed in a high proportion of patients in a two-year follow-up study [&lt;ulink linkID="1653443" linkType="Reference"&gt;1653443&lt;/ulink&gt;]. Additional  clinical data from 1927 patients with skin and soft tissue infections were  presented  at the same conference. The clinical success rate was highest for diabetic ulcer followed by superficial incision and diabetic foot infections [&lt;ulink linkID="1654629" linkType="Reference"&gt;1654629&lt;/ulink&gt;]. At the same conference, further clinical data were  presented.  Daptomycin treatment either as first-line or second-line, had an overall clinical success rate of 85%. Similar success rates were achieved for infections caused by coagulase-negative Staphylococci and S aureus [&lt;ulink linkID="1653444" linkType="Reference"&gt;1653444&lt;/ulink&gt;]. Further clinical data were also presented at the same conference demonstrating  that daptomycin was well tolerated and effective in treating left sided, right sided, and left and right sided infective endocarditis caused by gram-positive bacteria, including MRSA [&lt;ulink linkID="1653441" linkType="Reference"&gt;1653441&lt;/ulink&gt;].  At the same conference, further clinical data were  presented. The overall clinical success rate was 82% with &amp;gt; 6 mg/kg and 80% in the &amp;lt;/= 6 mg/kg dose group [&lt;ulink linkID="1653442" linkType="Reference"&gt;1653442&lt;/ulink&gt;]. In April 2016, further clinical data were presented at the 26th ECCMID in Amsterdam, the Netherlands. At the end of therapy, clinical success rate was found to be 85.5% (83.3% in &amp;gt; 6 to &amp;lt; 8 mg/kg/day group and 86.5% in &amp;gt;/=8 mg/kg/day group) in high dose group when compared with 78.4% in &amp;lt;/= 6 mg/kg/day dose group [&lt;ulink linkID="1751004" linkType="Reference"&gt;1751004&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2011, a randomized, active controlled, open label, parallel group, phase IV study (&lt;ulink linkID="74385" linkType="Protocol"&gt;NCT01287832&lt;/ulink&gt;; SJ1210-01; IND 109,614) was planned in the US, to assess the safety and efficacy of high-dose daptomycin compared with high-dose vancomycin in patients with bacteremia caused by S aureus isolates with high vancomycin MICs (expected n = 278). The primary endpoint was clinical success. At that time, the study was due to begin in February 2011 and complete in December 2014 [&lt;ulink linkID="1165286" linkType="Reference"&gt;1165286&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By January 2011, a trial of high-dose daptomycin (10 mg/kg/day) compared with standard-of-care therapy (either vancomycin or &lt;ulink linkID="12927" linkType="Drug"&gt;teicoplanin&lt;/ulink&gt;) in patients (n = 38) with MRSA bacteremia treated for 28 days had been initiated and patient enrollment was complete [&lt;ulink linkID="1172820" linkType="Reference"&gt;1172820&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2010, data from a 5-year study (2005 to 2009) on the antimicrobial activity of daptomycin and comparator agents tested against MRSA and VRE in US medical centers were presented at the 48th Infectious Diseases Society of America meeting in Vancouver, Canada. Daptomycin exhibited sustained activity against various clinical isolates of MRSA and VRE, and more than 99.9% of isolates were susceptible to the drug. Daptomycin demonstrated greater potency compared with vancomycin and &lt;ulink linkID="11036" linkType="Drug"&gt;linezolid&lt;/ulink&gt;. The potency of daptomycin was not affected by oxacillin or vancomycin resistance among S aureus or enterococci isolates, respectively [&lt;ulink linkID="1172820" linkType="Reference"&gt;1172820&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2010, an analysis of data from patients with renal impairment was presented at the 50th ICAAC meeting in Boston, MA. Target daptomycin exposure was achieved with 6 mg/kg thrice weekly or every other day for hemodialysis patients, and every other day in patients with severe renal impairment without dialysis or on continuous ambulatory peritoneal dialysis  [&lt;ulink linkID="1127316" linkType="Reference"&gt;1127316&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2010, a multicenter, randomized, single blind, active controlled, parallel group, phase IV study (&lt;ulink linkID="65811" linkType="Protocol"&gt;NCT01104662&lt;/ulink&gt;; DAP-RENSE-08-05; RENSE) began in the US, to assess the safety and efficacy of daptomycin compared with vancomycin in patients with cSSSI or bacteremia and renal impairment (expected n = 120). The primary endpoint was the incidence of treatment-emergent creatine phosphokinase (CPK) elevations &amp;gt; 500 U/L above baseline. The study was expected to complete in April 2012 [&lt;ulink linkID="1165289" linkType="Reference"&gt;1165289&lt;/ulink&gt;]. In October 2012, the trial was terminated [&lt;ulink linkID="1165289" linkType="Reference"&gt;1165289&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2008, a single blind, parallel assignment, randomized, phase IV study (&lt;ulink linkID="22554" linkType="Protocol"&gt;NCT00711802&lt;/ulink&gt; ; DAP-PEDS-07-03) was initiated in  the  US, India and Panama, to assess the safety, efficacy and pharmacokinetics of the drug in pediatric subjects (n = 420) with skin and skin structure infections. At that time, the study was expected to complete in April 2015 [&lt;ulink linkID="1635378" linkType="Reference"&gt;1635378&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2008, Cubist had initiated a trial of high-dose daptomycin (10 mg/kg) in patients with MRSA infection treated for 28 to 42 days, in comparison to vancomycin. Data were expected in 2011 [&lt;ulink linkID="957624" linkType="Reference"&gt;957624&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2008, a 4-week, phase IV study (&lt;ulink linkID="10510" linkType="Protocol"&gt;NCT00638157&lt;/ulink&gt;; 4IE), began in patients (n = 60), with S aureus infective endocarditis. Patients would be randomized to receive daptomycin (6 mg/kg every 24 h) alone or with initial combination gentamicin treatment. The primary endpoint was the incidence of adverse events at the end of the study. At that time, the study was due to be completed in February 2011 [&lt;ulink linkID="957308" linkType="Reference"&gt;957308&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2007, Cubist began a non-randomized, open-label pilot phase IV study (&lt;ulink linkID="11392" linkType="Protocol"&gt;NCT00572260&lt;/ulink&gt;) in the US, of daptomycin for antimicrobial prophylaxis in 200 patients undergoing cardiac valve replacement and coronary artery bypass grafting (CABG) who were at increased risk for infection due to MRSA. Patients would receive daptomycin (6 mg/kg iv) as a single preoperative dose within 30 min prior to surgery. The trial was expected to be completed in May 2008; however, it was terminated by November 2008 [&lt;ulink linkID="876768" linkType="Reference"&gt;876768&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2007, a 12-patient phase I study (&lt;ulink linkID="15393" linkType="Protocol"&gt;NCT00490737&lt;/ulink&gt;) began to evaluate daptomycin's potential in the prevention of infection in patients treated for end-stage renal disease. The study was expected to be completed in June 2008 [&lt;ulink linkID="876777" linkType="Reference"&gt;876777&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2006, data were presented at the 46th ICAAC meeting in San Francisco, CA. In  a  retrospective Cubicin Outcomes Registry and Experience (CORE 2005) study, 61 clinically evaluable patients with non-catheter related bacteremia received an average dose of 5.2 mg/kg daptomycin, for a median duration of 13 days. Clinical success was seen in 79% of all patients, with 87.5 and 72% success rates in patients with MRSA and vancomycin-resistant enterococcus infections. The drug was well tolerated, with adverse effects reported by 13% of patients [&lt;ulink linkID="687203" linkType="Reference"&gt;687203&lt;/ulink&gt;].  In a further CORE analysis, daptomycin (mean dose 5 mg/kg for 29 days) was shown to be effective and well tolerated in 26 patients with septic arthritis [&lt;ulink linkID="687217" linkType="Reference"&gt;687217&lt;/ulink&gt;].  In a  CORE study in  124 patients with osteomyelitis caused by Gram-positive bacteria, daptomycin   was shown to be effective (94% success rate), when used  alone  [&lt;ulink linkID="687218" linkType="Reference"&gt;687218&lt;/ulink&gt;]. Further data were presented in December 2007, at the 49th ASH meeting in Atlanta, GA, from a retrospective analysis of daptomycin use in cancer patients with neutropenia, showing that the degree of neutropenia did not affect the treatment outcome [&lt;ulink linkID="858225" linkType="Reference"&gt;858225&lt;/ulink&gt;]. In December 2008, retrospective data were presented at the 50th ASH meeting in San Francisco, CA. CORE 2006 established that most patients in the registry had an enterococcal infection and that 90% of patients had received successful treatment [&lt;ulink linkID="967077" linkType="Reference"&gt;967077&lt;/ulink&gt;]. In June 2010, further CORE data were published. The clinical success rate was 94%, and clinical success was observed regardless of vancomycin MIC [&lt;ulink linkID="1305902" linkType="Reference"&gt;1305902&lt;/ulink&gt;]. In September 2010, analyses of CORE 2005-9 were presented at the 50th ICAAC meeting in Boston, MA. In patients with MRSA bacteremia, no difference between clinical success rate or time to clinical response was seen between patients who received prior vancomycin therapy or first-line treatment with daptomycin  [&lt;ulink linkID="1126302" linkType="Reference"&gt;1126302&lt;/ulink&gt;].  In patients with renal insufficiency, daptomycin had an overall clinical success rate of 81%. Significantly lower success rates were seen in patients with a creatinine clearance rate (CrCl)  &amp;lt; 30 ml/min compared to patients with a CrCl of 30 to &amp;lt; 50 ml/min; however, there was no difference in the time to clinical response between the groups [&lt;ulink linkID="1126290" linkType="Reference"&gt;1126290&lt;/ulink&gt;]. Clinical success was reported in 87% of neutropenic patients; the success rate did not significantly differ by degree of neutropenia, causative pathogen or type of infection. Doses of daptomycin &amp;gt;/= 6 mg/kg were associated with significantly higher success rates in this patient population  [&lt;ulink linkID="1126287" linkType="Reference"&gt;1126287&lt;/ulink&gt;]. In October 2012, further data of daptomycin at higher doses (&amp;gt;/= 10 mg/kg)  were presented at IDweek 2012 in San Diego, CA. Of 5482 patients enrolled in CORE study, only 44 received daptomycin at &amp;gt;/= 10 mg/kg doses. Among the 38 patients evaluable for efficacy, the overall clinical success rate was 82%, with 42% patients were cured and 15% improved [&lt;ulink linkID="1331602" linkType="Reference"&gt;1331602&lt;/ulink&gt;]. In October 2013, further data were presented from the  multicenter, retrospective, observational chart review registry at IDWeek 2013 in San Francisco, CA. Outcomes were successful in 58 patients. Overall, the proportions of patients with improved, failed and cured outcome were 42, 6 and 52%, respectively [&lt;ulink linkID="1482017" linkType="Reference"&gt;1482017&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pediatric studies&lt;/subtitle&gt;In December 2012, a phase IV, randomized, single-blind, parallel-group trial (&lt;ulink linkID="98498" linkType="Protocol"&gt;NCT01728376&lt;/ulink&gt;; DAP-PEDBAC-11-02) began in to assess the safety and efficacy of daptomycin versus standard of care in pediatric patients aged 2 to 17 years with bacteremia caused by S aureus. In January 2015, recruitment was ongoing. At that time, the trial was expected to complete in December 2015 [&lt;ulink linkID="1650427" linkType="Reference"&gt;1650427&lt;/ulink&gt;]. In October 2016, clinical data were presented at the 2016 IDWeek in New Orleans, LA. At the test of cure (TOC) visit after 7 to 14 days, favorable clinical response was achieved by 88.2 and 77.3%, 85.0 and 87.5%, 94.1 and 77.8%, and 85.7 and 60.0% of total, 1 to 6 years, 7 to 11 years and 12 to 17 years of daptomycin and SOC-treated patients, respectively. In total population and patients of age groups 1 to 6, 7 to 11 and 12 to 17 years treated with daptomycin and SOC, &amp;gt;/= 1 adverse events (AEs) were reported by 36 and 20, 15 and 6, 12 and 9, 9 and 5 patients, respectively; and &amp;gt;/= 1 treatment-related AEs were reported by 8 and 4, 3 and 1, 5 and 1, and 0 and 2 patients, respectively [&lt;ulink linkID="1866357" linkType="Reference"&gt;1866357&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2009, a phase I, non-randomized, single-group, open-label study (&lt;ulink linkID="62315" linkType="Protocol"&gt;NCT01019395&lt;/ulink&gt;; DAP-PEDS-09-01) was initiated in the US, to evaluate the safety and pharmacokinetics of single-dose daptomycin with concurrent standard antibiotic therapy for proven or suspected gram-positive infection  in children (estimated n = 18) aged 3 months to 2 years. The study was expected to be completed in November 2011 [&lt;ulink linkID="1198194" linkType="Reference"&gt;1198194&lt;/ulink&gt;]. In October 2012, clinical data from pediatric patients (n = 19) receiving daptomycin (4 and 6 mg/kg in patients aged between 3 and 12 months, and 13 and 24 months, respectively, 30-min infusion) were presented at IDweek 2012 in San Diego, CA. Doses of 9 and 12 mg/kg/day (both in a 1-h infusion) were predicted to be equivalent to adult exposures (target AUC values) in pediatric patients aged between 3 months and 6 years of age  to achieve efficacious therapeutic exposures for the treatment of cSSSI (494 microg.h/ml) and bacteremia (632 microg.h/ml), respectively [&lt;ulink linkID="1331589" linkType="Reference"&gt;1331589&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2008, Cubist began a multicenter, evaluator blinded, randomized and comparative phase IV safety and efficacy study (&lt;ulink linkID="22554" linkType="Protocol"&gt;NCT00711802&lt;/ulink&gt;) in the US of daptomycin in pediatric subjects (expected n = 339) aged 2 to 17 years with cSSSI caused by Gram-positive pathogens. Patients would receive age-dependent doses of iv daptomycin  over a period of up to 14 days. The trial was expected to be completed by January 2011. In October 2013, the trial was completed [&lt;ulink linkID="1031468" linkType="Reference"&gt;1031468&lt;/ulink&gt;].&lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Complicated skin and soft tissue infection&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In June 2004, results from two pivotal phase III trials of daptomycin in patients with cSSTI caused by Gram-positive organisms were published in Clinical Infectious Diseases.  Patients (n = 1092) with cSSTI needing hospitalization were enrolled in the trials, 534 receiving daptomycin and 558 receiving either a semisynthetic penicillin or vancomycin. Daptomycin displayed similar activity to the penicillin and vancomycin against both MSSA and MRSA, and was safe and well tolerated [&lt;ulink linkID="544920" linkType="Reference"&gt;544920&lt;/ulink&gt;], [&lt;ulink linkID="544859" linkType="Reference"&gt;544859&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2003, Cubist made daptomycin available for a compassionate use protocol designed to treat patients with Gram-positive bacterial infections that were unable to be treated with other therapies [&lt;ulink linkID="485052" linkType="Reference"&gt;485052&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2002,  data were presented at the 12th ECCMID meeting in Milan, Italy. In two phase III trials involving approximately 1100 patients with cSSTI, 82% of the evaluable patients were cured at a dose of 4 mg/kg qd, this cure rate was similar to that of standard therapy. However, 63% of patients receiving daptomycin only, required 4 to 7 days of therapy compared to 33% on standard therapy. The frequency of adverse side effects, such as nausea or gastrointestinal toxicity, was similar for both daptomycin and conventional therapy [&lt;ulink linkID="451297" linkType="Reference"&gt;451297&lt;/ulink&gt;], [&lt;ulink linkID="455877" linkType="Reference"&gt;455877&lt;/ulink&gt;]. In September 2003, similar data were presented at the 43rd ICAAC meeting in Chicago, IL [&lt;ulink linkID="503759" linkType="Reference"&gt;503759&lt;/ulink&gt;]. Similar data were presented in March 2004, at the Sixth SMi Superbugs &amp;amp; Superdrugs: A Focus on Antibacterials meeting in London, UK. There was a slightly significant trend towards shorter duration of treatment in the daptomycin group. Daptomycin was equivalent to a comparator for all species evaluated, including MRSA and VRE [&lt;ulink linkID="526516" linkType="Reference"&gt;526516&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2001, clinical data  were presented at the 41st ICAAC meeting in Chicago, IL. Results from a phase III evaluator-blinded, phase III study of cSSTI showed that treatment with daptomycin (4 mg/kg/day) produced comparable results to either semi-synthetic penicillin (4 to 12 g/day) or vancomycin (1 g bid). However, daptomycin treatment showed advantages in patients with particular risk factors [&lt;ulink linkID="422327" linkType="Reference"&gt;422327&lt;/ulink&gt;]. Similar data were presented in September 2003, at the 43rd ICAAC meeting in Chicago, IL [&lt;ulink linkID="503760" linkType="Reference"&gt;503760&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2000, Cubist was performing an identical phase III trial (Study 9801) at multiple centers in the US [&lt;ulink linkID="393592" linkType="Reference"&gt;393592&lt;/ulink&gt;], [&lt;ulink linkID="401859" linkType="Reference"&gt;401859&lt;/ulink&gt;]. Enrollment for this study was completed by July 2001 [&lt;ulink linkID="415799" linkType="Reference"&gt;415799&lt;/ulink&gt;]. In October 2001, Cubist presented data from Study 9801 (the second pivotal phase III trial of daptomycin) at the Infectious Disease Society of America meeting in San Francisco, CA. The data showed that daptomycin achieved the required endpoint of equivalence to the comparator agents based on criteria set forth in the protocol previously reviewed by the FDA. In all study populations analyzed, the clinical success rates ranged from 65 to 75% in the daptomycin arm, versus 64 to 75% in the comparator arm. Combining the data from Study 9801 with the data from the first phase III cSSTI trial (Study 9901) revealed that the clinical success rates in the overall cSSTI program ranged from 74 to 85% in the daptomycin arm, versus 73 to 84% in the comparator arm. In Study 9801, clinically successful patients receiving daptomycin required fewer days of iv therapy than patients receiving the comparator agents by a 2 to 1 ratio. The incidence of total adverse events in Study 9801 was similar in both arms of the trial [&lt;ulink linkID="427162" linkType="Reference"&gt;427162&lt;/ulink&gt;], [&lt;ulink linkID="424439" linkType="Reference"&gt;424439&lt;/ulink&gt;]. Additional data from Study 9801 presented in May 2002, revealed that daptomycin showed a significantly faster time to defervescence, 2 days versus 3 days for the comparator arm [&lt;ulink linkID="450313" linkType="Reference"&gt;450313&lt;/ulink&gt;], [&lt;ulink linkID="469625" linkType="Reference"&gt;469625&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2000, enrollment of Study 9901, the first phase III cSSTI trial, was complete. This randomized, prospective, evaluator-blinded trial conducted at multiple centers outside the US enrolled a total of 562 patients. The primary endpoints of the study were efficacy and the secondary endpoints were bacteriological efficacy, duration of iv therapy and time to defervescence. Daptomycin was being compared to vancomycin, oxacillin or nafcillin and will be required to show equivalence to the comparator agents. In April 2001, results of this trial were reported at the 11th European Congress of Clinical Microbiology and Infectious Diseases in Istanbul, Turkey. These data showed that daptomycin achieved the required endpoint of statistical significance to comparator agents; in all study populations analyzed, the clinical success rates ranged from 81 to 91% in the daptomycin arm, versus 81 to 92% in the comparator arm. The microbiological responses were also virtually identical (74 and 75%, respectively) indicating the equivalence of the two treatments. Clinically successful patients receiving daptomycin required fewer days of iv therapy than patients receiving the comparator agents. In addition, the incidence of total adverse events was similar in both arms of the trial [&lt;ulink linkID="404002" linkType="Reference"&gt;404002&lt;/ulink&gt;], [&lt;ulink linkID="406671" linkType="Reference"&gt;406671&lt;/ulink&gt;]. In September 2001, additional data from Study 9901 were released. An analysis of the clinical success of daptomycin in the treatment of certain subpopulations showed that both dual infection (S aureus and hemolytic Streptococci) and diabetes mellitus are independent, significant risk factors for poor clinical outcome in cSSTI. Further analysis revealed that, among patients with dual infections, daptomycin demonstrated a trend towards improved clinical response when compared to standard therapy (82 vs 71%). In addition, in patients with diabetes mellitus, daptomycin showed a trend towards fewer days of iv therapy compared to standard therapy (20  versus 33 days) [&lt;ulink linkID="422891" linkType="Reference"&gt;422891&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 1999, Cubist filed an IND with the FDA to begin two phase III trials for daptomycin in patients with cSSTI due to Gram-positive bacterial strains. Each trial was to enroll 400 patients (200 receiving daptomycin and 200 receiving placebo). Preliminary results of the trial were reported in March 2001; the primary endpoint of demonstrating equivalency to comparator agents was achieved [&lt;ulink linkID="401859" linkType="Reference"&gt;401859&lt;/ulink&gt;]. Cubist filed for approval to commence phase III trials in six EU countries (including the UK) and Israel in July 1999. The UK trial aimed to evaluate the compound against cSSTI due to Gram-positive bacteria. Daptomycin was to be administered qd iv [&lt;ulink linkID="331941" linkType="Reference"&gt;331941&lt;/ulink&gt;]. The trial was successfully completed in April 2001 [&lt;ulink linkID="405233" linkType="Reference"&gt;405233&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In December 2005, clinical data were presented at the 45th ICAAC meeting in Washington DC. In a phase I dose-ascending study, iv doses of daptomycin of up to 12 mg/kg daily were tolerated for 14 days by healthy volunteers. The most common adverse events were headache (27.8%), aphthous stomatitis (11.1%), constipation (11.1%) and arthralgia (11.1%) [&lt;ulink linkID="641174" linkType="Reference"&gt;641174&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In March 2001, phase I data on daptomycin were presented at the 5th International Summit on Antibacterial Drug Discovery and Development, in Princeton, NJ. Efficacy and safety studies against Gram-positive bacteria using doses of 4, 6 and 8 mg/kg daptomycin administered every 24 h for 14 days revealed no adverse events [&lt;ulink linkID="404744" linkType="Reference"&gt;404744&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 1999, clinical pharmacokinetic studies in healthy volunteers had been completed and showed that daptomycin at doses up to 6 mg/kg iv produced linear AUC and Cmax values. Plasma clearance was low, due in part to high protein binding (90 to 94%). Volume of distribution was also low, due to the inability of daptomycin to cross cell membranes. Daptomycin's terminal half-life was 8.5 h and was excreted mainly via the kidney. Urinary recovery was about 80% of the dose, of which 66% was intact drug. Doses should be adjusted in line with creatinine clearance values [&lt;ulink linkID="335865" linkType="Reference"&gt;335865&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;OTHER STUDIES&lt;/subtitle&gt;In April 2016, clinical data from a prospective pilot study which evaluated the efficacy, safety and pharmacokinetics of daptomycin versus vancomycin for the treatment of proven or suspected infections with methicillin-resistant staphylococci or beta-lactam-resistant enterococci in 32 neutropenic cancer patients were presented at the 26th ECCMID in Amsterdam, the Netherlands. Patients were randomized (2:1) to receive empirical therapy with daptomycin (6 to 8 mg/kg/day, 2-min infusion) or vancomycin (15 mg/kg bid) for &amp;gt;/= 7 days, in addition to conventional broad-spectrum beta-lactam therapy. In the modified intention-to-treat population, global response (clinical + microbiological; primary endpoint) at the end of therapy was observed in nine out of ten patients and in four out of four patients in daptomycin and vancomycin groups, respectively [&lt;ulink linkID="1751167" linkType="Reference"&gt;1751167&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2015, clinical data were presented from post hoc analysis of four completed clinical studies at the 2015 ICAAC/ICC Meeting in San Diego, CA. Systemic clearance (ml/h), systemic clearance/body weight (ml/h/kg), Vss (ml), Vss/body weight (ml/kg), renal clearance (ml/h), renal clearance/body weight (ml/h/kg), distribution (h) and terminal elimination (h) values were 231, 1458, 144, 138, 13.7, 0.390 and 4.77, respectively in patients with age &amp;lt; 2 years, 354, 19.4, 2324, 131, 212, 11.6, 0.421 and 4.97 , respectively in patients with age 2 to 6 years, 592, 16.1, 4756, 126, 355, 9.6, 0.489 and 5.66, , respectively in patients with age 7 to 11 years and 774, 10.8, 7825, 111, 465, 6.5, 0.555 and 7.73, respectively in patients with age 12 to 17 years [&lt;ulink linkID="1694057" linkType="Reference"&gt;1694057&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Endocarditis&lt;/subtitle&gt;&lt;subtitle&gt; and bacteremiaPhase III&lt;/subtitle&gt;In March 1999, pivotal phase III trials and a phase II open-label trial began to evaluate three dose regimens of daptomycin in the treatment of bloodstream infections not associated with endocarditis [&lt;ulink linkID="316799" linkType="Reference"&gt;316799&lt;/ulink&gt;]. In May 2000, Cubist filed an expansion of the protocol for this study to include endocarditis patients [&lt;ulink linkID="367769" linkType="Reference"&gt;367769&lt;/ulink&gt;]. In September 2002, Cubist began enrolling patients in a multicenter, randomized, open-label phase III trial. The study was to compare daptomycin dosed 6 mg/kg iv once daily, with conventional iv therapy (nafcillin, 2 g every 4 h or vancomycin, 1 g every 12 h) in the treatment of infective endocarditis and S aureus bacteremia [&lt;ulink linkID="463180" linkType="Reference"&gt;463180&lt;/ulink&gt;]. Between September 2003 and By October 2004, four safety reviews by an independent data monitoring committee of the study had recommended it continue [&lt;ulink linkID="507003" linkType="Reference"&gt;507003&lt;/ulink&gt;], [&lt;ulink linkID="530270" linkType="Reference"&gt;530270&lt;/ulink&gt;], [&lt;ulink linkID="552564" linkType="Reference"&gt;552564&lt;/ulink&gt;], [&lt;ulink linkID="566969" linkType="Reference"&gt;566969&lt;/ulink&gt;]. In November 2004, the trial had completed enrollment of more than 230 patients; the FDA, which had originally requested that patients with left-sided endocarditis be enrolled, but due to enrollment difficulties, agreed that further enrollment of patients with left-sided endocarditis was not required for a label-expansion of daptomycin for the treatment of right-sided endocarditis and/or complicated bacteremia [&lt;ulink linkID="570087" linkType="Reference"&gt;570087&lt;/ulink&gt;]. In February 2005, the treatment phase of the trial was completed and all patients had entered the follow-up period of the trial. At that time, a fifth safety review had been completed [&lt;ulink linkID="586383" linkType="Reference"&gt;586383&lt;/ulink&gt;]. In June 2005, daptomycin its primary endpoints of non-inferiority [&lt;ulink linkID="614728" linkType="Reference"&gt;614728&lt;/ulink&gt;]. Daptomycin had a higher success rate than standard care for the treatment of S aureus endocarditis and bacteremia. In the intent-to-treat (ITT) population, 23% of 235 patients were diagnosed with S aureus endocarditis and 51% were diagnosed with complicated S aureus bacteremia. 139 patients were in the per protocol (PP) population. The overall success rates in the ITT and PP populations were higher than the success rates seen in the comparator arm with the greatest difference observed in the subset of patients with MRSA [&lt;ulink linkID="609977" linkType="Reference"&gt;609977&lt;/ulink&gt;]. Further results from this trial (study DAP-IE-01-02) were published in August 2006, demonstrating non-inferiority of daptomycin relative to standard-of-care therapy. In the ITT analysis, success rates at test of cure were 44.2% in 120 daptomycin-treated patients compared to 41.7% in 115 comparator-treated patients; success rates were similar in complicated bacteremia patients and in patients with right-sided endocarditis. Adverse events in daptomycin and comparator treatments were similar, including anemia, diarrhea and nausea [&lt;ulink linkID="684749" linkType="Reference"&gt;684749&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In April 2002 clinical data were presented at the 12th ECCMID meeting in Milan, Italy. In a randomized, open-label phase II study of 12 patients with bacteremia, all patients receiving 4 or 6 mg/kg daptomycin every 24 h were cured compared to only 64% of patients receiving vancomycin (1g bid) [&lt;ulink linkID="451297" linkType="Reference"&gt;451297&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2000, expanded data from a phase II bacteremia trial were presented at the 10th European Congress of Microbiology and Infectious Diseases meeting in Stockholm, Sweden. The multicenter, open-label studies focused on patients diagnosed with bacteremia and patients who were refractory, resistant or contraindicated (RRC) to other therapies. The combined data include results from 101 patients; at 4 mg/kg in a qd regimen, daptomycin had an overall success rate of 92% in the modified intent-to-treat population and 100% on clinically evaluable patients. In terms of microbiological eradication, daptomycin demonstrated a 75% and 93% success rate, respectively. Qd dosing of daptomycin appeared to be safe and effective in the treatment of bacteremia and Gram-positive infections [&lt;ulink linkID="369271" linkType="Reference"&gt;369271&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2000,  data were presented at the CDC's 4th Decennial Conference on Nosocomial and Healthcare-associated Infections in Atlanta, GA. These results showed that daptomycin (4 mg/kg, qd) had a 91% overall clinical success rate (19/21) and an 86% success rate (12/14) compared to 69% for vancomycin 1 g bid, in patients infected with a vancomycin-resistant pathogen or who were refractory to vancomycin [&lt;ulink linkID="358494" linkType="Reference"&gt;358494&lt;/ulink&gt;], [&lt;ulink linkID="384564" linkType="Reference"&gt;384564&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 1999, interim results from phase II trials of daptomycin were presented at the 39th ICAAC meeting in San Francisco, CA. The data analysis showed that patients treated with high-dose daptomycin (6 mg/kg daily) showed no difference in adverse events compared with patients in the comparator arm (administered either vancomycin or &lt;ulink linkID="52285" linkType="Drug"&gt;oxacillin&lt;/ulink&gt;), or patients treated with lower doses of daptomycin (4 mg/kg daily or 3 mg/kg bid) [&lt;ulink linkID="341469" linkType="Reference"&gt;341469&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Completed phase II studies have shown daptomycin, in iv form, to be relatively safe and effective against bacteremia and SST infections caused by bacteria such as MRSA, Streptococcus pyogenes [&lt;ulink linkID="268910" linkType="Reference"&gt;268910&lt;/ulink&gt;] and Enterococcus spp [&lt;ulink linkID="335865" linkType="Reference"&gt;335865&lt;/ulink&gt;]. There may be some associations between high-dose daptomycin use and skeletal muscle toxicity; however, the preliminary human safety profile of daptomycin was favorable in comparison to the other major classes of Gram-positive antimicrobials [&lt;ulink linkID="335865" linkType="Reference"&gt;335865&lt;/ulink&gt;]. Daptomycin has no known drug interactions or CNS effects [&lt;ulink linkID="383597" linkType="Reference"&gt;383597&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In September 2003, clinical data were presented at the 43rd ICAAC meeting in Chicago, IL. A population analysis was used to identify factors contributing to intersubject variability (ISV) in daptomycin PK in 129 subjects with acute bacterial infections and 153 noninfected subjects, who were given single or multiple doses of 4 to 8 mg/kg daptomycin every 24 h by 30-min iv infusion. Clearance of daptomycin correlated with markers of renal function, and it was concluded that reduced clearance in subjects with severe renal impairment may necessitate adjustment of dosing regimens to achieve systemic exposures of daptomycin similar to those in subjects with normal renal function. Relationships between body weight and rate and extent of extravascular distribution support the dosing of daptomycin on a mg/kg basis [&lt;ulink linkID="503043" linkType="Reference"&gt;503043&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other Studies&lt;/subtitle&gt;In  October 2014,  data from a multicenter, restrospective matched-cohort were presented at the 2014 IDWeek in Philadelphia, PA. The overall composite failure was observed to be 35%. At the end of therapy, failure rates were lower in the daptomycin group compared with vancomycin group. At day 4, the clearance of bacteremia was 76%. Similar rates of 30-day all cause re-admission rates were observed in both the treatment groups [&lt;ulink linkID="1598746" linkType="Reference"&gt;1598746&lt;/ulink&gt;]. In September 2015, further clinical data were presented from 250 patients (125 matched pairs) at the 2015 ICAAC/ICC Meeting in San Diego, CA. Less patients required change of MRSA therapy in daptomycin cohort (12.8%) when compared with vancomycin cohort (29.4%). A 60-day infection-related readmission was lower in daptomycin cohort (6.4%) when compared with vancomycin cohort (12%) [&lt;ulink linkID="1692758" linkType="Reference"&gt;1692758&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2013, data from a multicenter, retrospective study were presented at IDWeek 2013 in San Francisco, CA. Hospitalized adult patients (n = 93) received daptomycin (&amp;gt;6 mg/kg) for at least 3 days. The overall composite failure was 30% (n = 28 of 93). The proportions of patients with endocarditis, mycotic aneurysm/septic thrombophlebitis, unknown source, catheter, bone/joint, skin and abdominal/urinary infections who cleared bacteremia were  77, 67, 92, 98, 96, 100 and 100%, respectively, on day 7 [&lt;ulink linkID="1482077" linkType="Reference"&gt;1482077&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In  September 2012, data were presented from 37/51 patients at the 52nd ICAAC Meeting in San Francisco, CA.  The overall success rate was 76% (76% of patients were cured and 32% showed improvement). The success rate did not differ by pathogen; 69% for E faecium and 75% for E faecalis.  The rate of clinical success was not dose-dependent; 77% at &amp;lt; 8 mg/kg, and 71% at &amp;gt;/= 8 mg/kg dose. Patient demographics, pathogens, prior antibiotic therapy and dose were found to affect the success rate. The success rate was 86% in patients with prosthetic valve. Success rates were not found to differ by vancomycin susceptibility [&lt;ulink linkID="1319630" linkType="Reference"&gt;1319630&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Community-acquired pneumonia and urinary tract infections&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;By September 2001, enrollment in a community-acquired pneumonia (CAP) study, CAP1, had been completed, with 729 patients enrolled into the randomized, double-blinded trial. The primary endpoint in the study, to compare daptomycin dosed at 4 mg/kg qd to &lt;ulink linkID="44384" linkType="Drug"&gt;ceftriaxone&lt;/ulink&gt; dosed at 2 g qd, was to be clinical efficacy [&lt;ulink linkID="421366" linkType="Reference"&gt;421366&lt;/ulink&gt;], [&lt;ulink linkID="424996" linkType="Reference"&gt;424996&lt;/ulink&gt;]. In January 2002, preliminary results for CAP1, analyzing data from 714 patients, were reported and indicated that the primary endpoint of demonstrating non-inferiority to an active comparator agent  ceftriaxone was not achieved in the overall international study. However, the endpoint was achieved in the intent-to-treat and clinically evaluable cohorts representing the North American and Western European populations. The daptomycin arm of the study in the clinically evaluable populations analyzed demonstrated a clinical success rate of 79% and the ceftriaxone arm demonstrated an 87% clinical success rate. While there are no apparent significant differences in key demographic parameters in the overall study, a strong geographic difference was observed. Daptomycin achieved higher success rates compared to ceftriaxone (72 versus 62%) in the North American intent-to-treat patient population. The clinical success rate in the clinically evaluable populations in North America and Western Europe was 85% for daptomycin and 84% for ceftriaxone. In March 2002, Cubist reported that it would undertake a complete reanalysis of the data from the CAP1 study. As a result of internal data analysis, the company believed a thorough review of the data by independent medical consultants was warranted to help clarify the CAP1 clinical trial results [&lt;ulink linkID="442733" linkType="Reference"&gt;442733&lt;/ulink&gt;]. Enrollment in the second phase III study (CAP2) was suspended pending further review and evaluation of the CAP data to consider a North American and Western European only trial for this indication [&lt;ulink linkID="436210" linkType="Reference"&gt;436210&lt;/ulink&gt;]; enrollment in CAP2 had been expected to enable planned mid-2002 regulatory filings [&lt;ulink linkID="421366" linkType="Reference"&gt;421366&lt;/ulink&gt;]. In August 2002, analysis of the CAP2 was completed; outcome trends from the initial analysis of 170 evaluable patients appeared to be consistent with the results seen in the CAP1 study, but were not meaningful given the small patient population [&lt;ulink linkID="460147" linkType="Reference"&gt;460147&lt;/ulink&gt;]. Similar data were reported in March 2004 at the Sixth SMi Superbugs &amp;amp; Superdrugs: A Focus on Antibacterials meeting in London, UK [&lt;ulink linkID="526516" linkType="Reference"&gt;526516&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2000, two  phase III trials in CAP and cUTI had begun. The company was planning two international studies in CAP and was to wait until at least one of those was done to file the NDA [&lt;ulink linkID="393026" linkType="Reference"&gt;393026&lt;/ulink&gt;]. In March 2001, the company anticipated completing the CAP studies by the end of 2001 [&lt;ulink linkID="401859" linkType="Reference"&gt;401859&lt;/ulink&gt;]. In July 2001, Cubist completed enrollment in its phase II/III feasibility study of daptomycin in complicated UTI caused by Gram-positive bacteria [&lt;ulink linkID="415799" linkType="Reference"&gt;415799&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In July 2000, the FDA approved the design of Cubist's phase III trials for daptomycin for the potential treatment of both CAP and cUTI [&lt;ulink linkID="376531" linkType="Reference"&gt;376531&lt;/ulink&gt;], [&lt;ulink linkID="368941" linkType="Reference"&gt;368941&lt;/ulink&gt;], [&lt;ulink linkID="369271" linkType="Reference"&gt;369271&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In April 2002  data were presented at the 12th ECCMID meeting in Milan, Italy. In a phase II trial in patients with UTI, 29 of 31 patients receiving daptomycin were cured compared to 28 of 30 patients receiving &lt;ulink linkID="44438" linkType="Drug"&gt;ciprofloxacin&lt;/ulink&gt; [&lt;ulink linkID="451297" linkType="Reference"&gt;451297&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In February 2002, Cubist disclosed preliminary results from a phase II feasibility trial investigating the safety and efficacy of daptomycin in the treatment of cUTI. The trial achieved its goal of demonstrating no differences between the microbiological and clinical cure rates for daptomycin versus the comparator agent across all patient populations. In addition, there were no meaningful differences in the adverse event profiles of the two agents in this study. The study involved 68 patients, half of whom received 4 mg/kg daptomycin qd and half of whom received ciprofloxacin 400 mg bid, both iv. The trial was a randomized, open-label, microbiologist- and evaluator-blinded, multicenter study conducted predominantly in Eastern Europe. The primary endpoint was microbiological efficacy in eradicating Gram-positive urinary tract pathogens in cases of cUTI in hospitalized patients; clinical efficacy was a secondary endpoint. In the evaluable population, daptomycin was 83% effective when evaluated microbiologically and 94% effective judged clinically. In the comparator arm, Cipro achieved 85% microbiological success and 93% clinical success. In addition, there were no observed clinical relapses in the daptomycin arm, while 7% of the patients relapsed in the comparator arm [&lt;ulink linkID="439841" linkType="Reference"&gt;439841&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Osteomyelitis&lt;/subtitle&gt;In August 2013, a randomized, double-blind, parallel-assigned, interventional phase III study (&lt;ulink linkID="150510" linkType="Protocol"&gt;NCT01922011&lt;/ulink&gt;; DAP-PEDOST-11-03) was planned to be initiated in pediatric patients (n = 204) with acute hematogenous osteomyelitis to compare the safety and efficacy of daptomycin with vancomycin or &lt;ulink linkID="52118" linkType="Drug"&gt;nafcillin&lt;/ulink&gt; in  the US, South America, Australia, Europe, Israel, Korea, Guatemala and Turkey. At that time, the trial was expected to be completed in  November 2016; in January 2014, the trial was initiated in the US and Italy; by March 2015, the trial was initiated in Australia, South America, Isreal, Korea and  Europe  [&lt;ulink linkID="1469277" linkType="Reference"&gt;1469277&lt;/ulink&gt;]. The trial completed in December 2016. In June 2017, data were reported; investigators' assessment of clinical improvement in pain, inflammation and limb function was 77.5% for daptomycin versus 82.9% for vancomycin/nafcillin, respectively (p = 0.421) [&lt;ulink linkID="1469277" linkType="Reference"&gt;1469277&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2007, a multinational, randomized, open label,  parallel group, phase II trial (&lt;ulink linkID="11506" linkType="Protocol"&gt;NCT00428844&lt;/ulink&gt;; DAP-OST-06-02) began, to assess the safety and efficacy of daptomycin compared with   comparator antibiotics in patients  with osteomyelitis associated with prosthetic joint infections caused by MRSA or coagulase-negative staphylococci (expected n = 75). The primary endpoint was incidence of elevated CPK, defined as CPK level greater than 500 U/l.The study completed in June  2010 [&lt;ulink linkID="887930" linkType="Reference"&gt;887930&lt;/ulink&gt;]. In July 2010, preliminary results were reported, showing that the study met its primary objectives. Adverse events were similar across all treatment groups. In addition, at 1 to 2 weeks post-treatment, both doses of daptomycin induced higher clinical response rates compared with the comparator therapy (vancomycin, teicoplanin or semi-synthetic penicillins) [&lt;ulink linkID="1115988" linkType="Reference"&gt;1115988&lt;/ulink&gt;]. Further data were presented at ECCMID in May 2011.Of 73 safety population subjects, a CPK elevation of &amp;gt;500 U/L occurred in 16% of patients taking daptomycin 6 mg/kg, 22% on  8mg/kg, and 8% for comparator subjects. Elevations were sustained in 2 daptomycin 6 mg/kg and 3 daptomycin 8 mg/kg subjects. In 68 intent-to-treat subjects, daptomycin had a higher blinded Sponsor-defined success rate (clinical and microbiologic response) at test of cure. Microbiological failure or discontinuation due to an adverse event accounted for most cases categorised as failures;  2 subjects (both daptomycin 6 mg/kg) failed for an unsatisfactory clinical response. Eradication rates at test of cure for MRSA were 3/5 daptomycin 6 mg/kg, 3/7 daptomycin 8 mg/kg, and 2/5 comparator; MSSA 8/11, 5/9, and 5/10, respectively; and coagulase-negative staphylococci 7/12, 7/11, and 13/15, respectively [&lt;ulink linkID="1261613" linkType="Reference"&gt;1261613&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other indications&lt;/subtitle&gt;In  September 2015, clinical data were presented from a single-center, retrospective, cohort study in 135 patients with vancomycin-resistant enterococcus blood stream infections (BSI) at the 2015 ICAAC/ICC Meeting in San Diego, CA. Patients received high-dose daptomycin or linezolid. Clinical success (primary endpoint) was observed in 72.5 and 72.6% of patients in daptomycin and linezolid groups, respectively. Median BSI duration post-study drug was one day shorter in daptomycin group when compared with linezolid [&lt;ulink linkID="1694408" linkType="Reference"&gt;1694408&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2012, data were presented from a multicenter study in patients with VRE infection (n = 262) at the 52nd ICAAC Meeting in San Francisco, CA. The overall success rate was 86%; the success rates in patients infected with VRE faecium and faecalis were 86 and 82%, respectively. Success rate was 86% among patients treated with concomitant beta-lactams (n = 122), and among patients receiving daptomycin in combination with gentamicin, linezolid, rifampin, tigecycline and tobramycin, the success rates were 85, 73, 75, 75 and 75%, respectively.  The overall clinical success rate for a dose of &amp;lt; 6 mg/kg was 80%, and 88% for doses &amp;gt;/= 6 mg/kg. Post-hoc subanalysis of patients showed that  the success rates were found to be higher (91, 89 and 71%) in patients with VRE having lower MIC values (&amp;lt;/= 1, 1.5 to 2, and 3 to 4 microg/ml, respectively). Daptomycin was  well tolerated [&lt;ulink linkID="1319629" linkType="Reference"&gt;1319629&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2002, data from a phase II trial of daptomycin in patients with febrile neutropenia and infections caused by vancomycin-resistant Enterococcus faecium (VRE) were presented at the 12th European Congress of Clinical Microbiology and Infectious Diseases in Milan, Italy. All patients involved in the trial had underlying acute myeloid leukemia or had recently undergone a bone marrow transplant. All patients had VRE bacteremia and received daptomycin in a variety of dosing regimens. Survival rates were 50% compared to 22% in the control group, and clinical or microbiological cure rates were 55%, compared to 33% in the control group [&lt;ulink linkID="449581" linkType="Reference"&gt;449581&lt;/ulink&gt;]. As of May 2002, a phase III trial in VRE infections was ongoing [&lt;ulink linkID="450141" linkType="Reference"&gt;450141&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In April 2017, in vitro data were presented at the 27th ECCMID in Vienna, Austria. Against MRSA-1, MRSA-2, MSSA-1 and MSSA-2, MRSA linezolid resistant and MSSA linezolid, the resistant fractional inhibitory concentration index observed with &lt;ulink linkID="30819" linkType="Drug"&gt;tedizolid&lt;/ulink&gt; were 0.5, 0.25, 0.25, 0.5, 0.5 and 2 mg/l, respectively, and &lt;ulink linkID="51430" linkType="Drug"&gt;fusidic acid&lt;/ulink&gt; had MIC values of 0.25, 0.25, 8, 0.125, 0.25 and 0.25, respectively. The MIC values observed with vancomycin + tedizolid combination were 0.63, 1.06, 1.06, 0.63, 0.75 and 1 mg/l, with tedizolid + daptomycin were 1.06, 1.06, 1.06, 0.75, 1.06 and 0.75 mg/l, with tedizolid + rifampicin were 0.63, 0.63, 1.06, 1, 0.63 and 0.75 mg/l, tedizolid + fusidic acid were 0.50, 0.31, 0.75, 0.50, 0.56 and 0.38 mg/l against MRSA-1, MRSA-2, MSSA-1, MSSA-2, MRSA linezolid resistant and MSSA linezolid, respectively [&lt;ulink linkID="1920551" linkType="Reference"&gt;1920551&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In  October 2016, preclinical data were presented at the 2016 IDWeek in New Orleans, LA. Daptomycin was equally potent against S aureus in both pediatric (100% susceptible) and adult patients (&amp;gt;/= 99.4% susceptible) across the USA and EU in 2012 and 2014. According to MIC50/90, daptomycin (0.25/0.5 microg/ml; 100% susceptible) was 2- to 4-fold more potent compared with linezolid (1/2 microg/; 100% susceptible) and vancomycin (1/1 microg/ml; 100% susceptible) against bloodstream S aureus isolates, irrespective of patient age or collection year [&lt;ulink linkID="1866289" linkType="Reference"&gt;1866289&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2015, preclinical data were presented at the 2015 ICAAC/ICC Meeting in San Diego, CA. Against MRSA675, 684, R8846 and R8847 strains, daptomycin had MIC value of 0.25, 2, 0.125 and 4 microg/ml, respectively when compared with ceftaroline (1, 1, 0.5 and 0.5 microg/ml, respectively) cefazolin (8, 2, 64 and 2 microg/ml, respectively), piperacillin (128, 64, 128 and 64 microg/ml, respectively), piperacillin + tazobactam (16, 16, 32 and 8 microg/ml, respectively), ampicillin (16, 8, 16 and 8 microg/ml, respectively), ampicillin +  sulbactam (4, 8, 8 and 4 microg/ml, respectively), daptomycin + tazobactam (0.25, 2, 0.125 and 4 microg/ml, respectively) and daptomycin + sulbactam (0.25, 2, 0.125 and 4 microg/ml, respectively [&lt;ulink linkID="1694047" linkType="Reference"&gt;1694047&lt;/ulink&gt;]. Further data were also presented at the same conference. Against C68 and HOU503 strains, daptomycin MIC values of 2 microg/ml, respectively were observed when compared with daptomycin + ampicillin (0.5 and 1 microg/ml, respectively) and daptomycin + ertapenem (0.25 and 0.5 microg/ml, respectively) and biofilm MIC of 4 microg/ml when compared with daptomycin + ampicillin (1 and 2 microg/ml, respectively) and daptomycin + ertapenem (0.5 and 1 microg/ml, respectively [&lt;ulink linkID="1692794" linkType="Reference"&gt;1692794&lt;/ulink&gt;]. Further data were also presented at the same conference. Daptomycin had MICs of 1 and 4 microg/ml on days 1 and 14, respectively. Daptomycin + ceftaroline + ampicillin combination had the greatest synergy. Greater survival was observed on day 14 isolate and hence reduced susceptibility was observed with LL-37 [&lt;ulink linkID="1694371" linkType="Reference"&gt;1694371&lt;/ulink&gt;]. Further data were also presented at the same conference. Deletion of liaR resulted in significant decrease of daptomycinsusceptibility with MICs changing from 3 to 0.064 microg/ml and 0.047 microg/ml in HOUF503 and HOU515F strains, respectively. Daptomycin tolerance was not mediated by repulsion of the antibiotic from the cell membrane [&lt;ulink linkID="1693309" linkType="Reference"&gt;1693309&lt;/ulink&gt;]. Further data were also presented at the same conference. Daptomycin-resistant strains with mprF SNPs in the bifunctional domain showed higher resistance to thrombin-induced platelet microbicidal protein killing when compared with daptomycin-resistant strains with SNPs in the synthase domain [&lt;ulink linkID="1693435" linkType="Reference"&gt;1693435&lt;/ulink&gt;]. Further data were also presented at the same conference. Combination exposure inactivated PBP1which resulted in more rapid and sustained killing when compared with combination exposure with beta-lactam which inactivated alternative PBPs. In Staphylococcus aureus, daptomycin + PBP1-selective beta-lactams resulted in an increased frequency of septation and cell wall abnormalities and decreased binding of daptomycin to staphylococcal membranes [&lt;ulink linkID="1694372" linkType="Reference"&gt;1694372&lt;/ulink&gt;]. Further data were also presented at the same conference. In daptomycin (6 mg/kg/24 h), daptomycin (6 mg/kg/24 h) + cloxacillin (2 g/4 h) and daptomycin (6 mg/kg/24 h) + fosfomycin (2 g/6 h) groups, 0, 8 and 10 animals were observed with sterile vegetations, respectively when compared with control and median log10 cfu/g of vegetation was 2, 0 and 0 IQR, respectively when compared with control (9 IQR) [&lt;ulink linkID="1692696" linkType="Reference"&gt;1692696&lt;/ulink&gt;]. At the same conference, further preclinical data were presented. Overall, prolonged exposure of daptomycin-nonsusceptibleMRSA to beta-lactams does not result in any predictable changes to daptomycin MICs [&lt;ulink linkID="1694382" linkType="Reference"&gt;1694382&lt;/ulink&gt;].  At the same conference, further preclinical data were presented. Against MRSA isolates from the Canadian intensive care units, susceptibility rates of &amp;gt; 99% were noted for daptomycin, vancomycin, linezolid and &lt;ulink linkID="8642" linkType="Drug"&gt;tigecycline&lt;/ulink&gt; [&lt;ulink linkID="1692883" linkType="Reference"&gt;1692883&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2015, preclinical data were presented at the 2015 ICAAC/ICC Meeting in San Diego, CA. All strains of Enterococcus faecalis were hypersusceptible to daptomycin with MIC &amp;lt;/= 0.25 microg/ml, after the deletion of liaR mutation [&lt;ulink linkID="1692822" linkType="Reference"&gt;1692822&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In  September 2014, data were presented at the 54th ICACC meeting in Washington, DC. Low dose colistin showed bactericidal action at 2 h in 100% isolates at the concentration of one quarter MIC when daptomycin was added to a final concentration of 8 microg/ml [&lt;ulink linkID="1590163" linkType="Reference"&gt;1590163&lt;/ulink&gt;]. Further data were presented at the same conference.  Activity of daptomycin against Enterococcus and Streptococcus species from South Africa was excellent compared with rest of the world [&lt;ulink linkID="1589217" linkType="Reference"&gt;1589217&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2005, preclinical data had been reported from studies in which the in vivo activity of daptomycin was compared to &lt;ulink linkID="44370" linkType="Drug"&gt;clindamycin&lt;/ulink&gt;, doxycycline and linezolid in a mouse model of thigh infection with three strains of community acquired MRSA. All strains were susceptible to all drugs. Daptomycin was more effective than in vitro and most effective at low inoculum levels [&lt;ulink linkID="641257" linkType="Reference"&gt;641257&lt;/ulink&gt;]. In vitro, daptomycin was generally bactericidal against staphylococci including MRSA in 3 to 6 h at concentrations of twice the MIC. It exhibited a broader spectrum of activity than several comparators but activity was decreased in the presence of serum [&lt;ulink linkID="641989" linkType="Reference"&gt;641989&lt;/ulink&gt;]. Bactericidal activity was retained for non-dividing S aureus [&lt;ulink linkID="641990" linkType="Reference"&gt;641990&lt;/ulink&gt;] and studies indicated that the mechanism of action of daptomycin might involve inhibition of peptidoglycan synthesis [&lt;ulink linkID="641751" linkType="Reference"&gt;641751&lt;/ulink&gt;]. The anti-MRSA activity of daptomycin, gentamycin and rifampin, alone and in combination, was assessed in vitro in human monocyte-derived macrophages. The 3-drug combination was most effective with 99.98% killing in 2 h without regrowth in 24 h [&lt;ulink linkID="641987" linkType="Reference"&gt;641987&lt;/ulink&gt;]. An MIC90 value of 1 microg/ml against MRSA was obtained for daptomycin, comparable to vancomycin and linezolid.  Daptomycin also demonstrated good activity against vancomycin-resistant enterococci [&lt;ulink linkID="642019" linkType="Reference"&gt;642019&lt;/ulink&gt;]. The in vitro bactericidal activity of daptomycin against recent  clinical isolates of MRSA and MSSA was consistently higher than that  of either vancomycin or linezolid [&lt;ulink linkID="641994" linkType="Reference"&gt;641994&lt;/ulink&gt;]. In an in vitro study involving 200 community-acquired and 50 hospital-acquired strains of MRSA, daptomycin demonstrated potent activity against all strains with MIC50 values of 0.25 to 0.5 microg/ml [&lt;ulink linkID="642012" linkType="Reference"&gt;642012&lt;/ulink&gt;]. MIC50 values of 0.5,  1 and 2 microg/ml  were obtained against VSSA/MSSA, VSSA/MRSA and heterogenous VISA strains, respectively [&lt;ulink linkID="641959" linkType="Reference"&gt;641959&lt;/ulink&gt;]. In a rat model of pneumococcal meningitis, daptomycin (50 mg/kg sc) was more effective at clearing bacteria from cerebrospinal fluid than ceftriaxone (100 mg/kg sc) and produced a less severe inflammatory host reaction [&lt;ulink linkID="641535" linkType="Reference"&gt;641535&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2004, preclinical data were presented at the 44th ICAAC meeting in Washington DC. Daptomycin (MIC =  0.25 to 1.0 microg/ml) was more effective than vancomycin, BAL-9141 and linezolid against MRSA clinical isolates [&lt;ulink linkID="571205" linkType="Reference"&gt;571205&lt;/ulink&gt;]. Daptomycin also showed activity against Clostridium difficile, Clostridium perfringens, Propionibacterium acnes, Finegoldia magna [&lt;ulink linkID="568567" linkType="Reference"&gt;568567&lt;/ulink&gt;], viridans group streptococci [&lt;ulink linkID="568566" linkType="Reference"&gt;568566&lt;/ulink&gt;] and Gram-positive pathogens [&lt;ulink linkID="568511" linkType="Reference"&gt;568511&lt;/ulink&gt;], [&lt;ulink linkID="568509" linkType="Reference"&gt;568509&lt;/ulink&gt;]. Daptomycin showed superior efficacy to vancomycin in a rabbit model of MSSA-induced meningitis [&lt;ulink linkID="568357" linkType="Reference"&gt;568357&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2004, preclinical data on daptomycin were presented at the Sixth SMi Superbugs and Superdrugs: A Focus on Antibacterials meeting in London, UK. In a preclinical study, dogs were administered 75 mg/kg daptomycin every 24 h or 25 mg/kg every 8 h. The 75-mg/kg group suffered less effect on the skeletal muscle than the 25-mg/kg group. Studies also showed that the drug does not penetrate well into the brochoalveolar lavage-epithelial lining fluid, where maximum concentrations of deptomycin were 2 to 3%. However, it showed good penetration into blood clots, the peritoneal tissue chamber and blister fluid. In a murine lung infection model, daptomycin had high efficacy in treating hematogenous S aureus pneumonia and anthrax infection. Daptomycin also showed cidality against vancomycin-resistant S aureus [&lt;ulink linkID="526229" linkType="Reference"&gt;526229&lt;/ulink&gt;], [&lt;ulink linkID="526516" linkType="Reference"&gt;526516&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2003,  data were presented at the 43rd ICAAC meeting in Chicago, IL. In a study testing the postantibiotic effect (PAE), subMIC effect (SME) and postantibiotic subMIC effect (PA-SME) of daptomycin against a variety of Gram-positive bacteria, daptomycin MIC values were all 0.125 to 0.5 microg/ml. PAE values were all between 1.0 to 6.2 h. The PA-SMEs were generally longer than the PAE for all the strains tested, indicating that subMIC levels of daptomycin extend the PAE [&lt;ulink linkID="503855" linkType="Reference"&gt;503855&lt;/ulink&gt;]. In another study presented at ICAAC 2003, the profile of daptomycin against four S pneumoniae strains was determined using the immunocompromized murine thigh model; the drug was administered sc in doses ranging from 0.625 to 10mg/kg qd to qid. Results showed that similar in vivo exposures in man would be expected to produce = 99% of the maximal kill of log10 7.1 observed here [&lt;ulink linkID="503385" linkType="Reference"&gt;503385&lt;/ulink&gt;]. Daptomycin was also shown to have good activity against Gram-positive bacteria resistant to other agents including linezolid and quinupristin/dalfopristin [&lt;ulink linkID="503666" linkType="Reference"&gt;503666&lt;/ulink&gt;], while further studies indicated that daptomycin, with or without rifampicin, &lt;ulink linkID="12978" linkType="Drug"&gt;moxifloxacin&lt;/ulink&gt; and gentamicin, may be useful against vancomycin intermediate S aureus (VISA), hetero-VISA (hVISA) and highly resistant isolates of S aureus [&lt;ulink linkID="503671" linkType="Reference"&gt;503671&lt;/ulink&gt;], [&lt;ulink linkID="503676" linkType="Reference"&gt;503676&lt;/ulink&gt;]. Daptomycin also demonstrated bactericidal activity by 12 h in 5 of 6 strains of linezolid/vancomycin-resistant Enterococcus Faecium when tested at concentrations clinically achievable with 8 mg/kg/day dosing; supplementation with albumin appeared necessary to accurately characterize the activity of daptomycin in relation to in vivo conditions [&lt;ulink linkID="503677" linkType="Reference"&gt;503677&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2003, preclinical data were presented at the 13th ECCMID meeting in Glasgow, UK, on the bactericidal activity of daptomycin against Gram-positive pathogens resistant to linezolid. Daptomycin had potent activity against all clinical strains tested including Staphylococcus epidermidis (MIC 0.5 mg/l) and Enterococcus spp (MIC 4 and 0.25 mg/l). Activity against vancomycin-resistant Enterococcus spp was also demonstrated (MIC 0.25 mg/L) [&lt;ulink linkID="489120" linkType="Reference"&gt;489120&lt;/ulink&gt;]. At the same meeting, data were presented from an in vitro study on the activity of daptomycin against Gram-positive uropathogens, which cause complicated urinary tract infections. Daptomycin was tested against a number of uropathogens from three different collections, including MSSA, MRSA and MSSE, and was found to be potent against all strains with MICs ranging from 1 mg/L and 2 mg/L [&lt;ulink linkID="490131" linkType="Reference"&gt;490131&lt;/ulink&gt;]. Further preclinical data were presented at the meeting demonstrating daptomycin's in vitro activity against VRE, linezolid-resistant VRE, MRSA and Streptococcus pneumoniae [&lt;ulink linkID="490449" linkType="Reference"&gt;490449&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Also in May 2003, data were also presented at the 103rd general meeting of the American Society for Microbiology, in Washington, DC. Daptomycin was shown to have synergistic in vitro activity in combination with &lt;ulink linkID="51474" linkType="Drug"&gt;rifampin&lt;/ulink&gt; and &lt;ulink linkID="51757" linkType="Drug"&gt;ampicillin&lt;/ulink&gt; against vancomycin-resistant enterococci (VRE). Bactericidal synergy was observed in 100% of MRSA strains at one half daptomycin MIC, and 61% at one quarter. In a rodent fibrin clot model of endocarditis caused by MRSA, daptomycin (50 mg/kg) effectively penetrated thrombin clots containing MRSA and that both vancomycin and linezolid were less effective than daptomycin in killing MRSA [&lt;ulink linkID="490484" linkType="Reference"&gt;490484&lt;/ulink&gt;], [&lt;ulink linkID="492697" linkType="Reference"&gt;492697&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2002, preclinical data  were presented at the 42nd ICAAC meeting in San Diego, CA. Daptomycin demonstrated activity (MIC = 0.125 to 0.5 microg/ml) against 346 pneumococci tested, irrespective of beta-lactam, macrolide or quinoline susceptibility status [&lt;ulink linkID="464538" linkType="Reference"&gt;464538&lt;/ulink&gt;]. Time-kill studies showed daptomycin to have measurable anti-pneumococcal activity after 1 h; after 24 h at 2-fold MIC, the agent was bactericidal against 6 to 8 strains [&lt;ulink linkID="464540" linkType="Reference"&gt;464540&lt;/ulink&gt;]. Daptomycin displayed potent activity, regardless of specimen source or geographic region, against isolates of staphylococci, enterococci, and streptococci, including isolates which have demonstrated resistance or multidrug resistance to agents marketed at that time [&lt;ulink linkID="464541" linkType="Reference"&gt;464541&lt;/ulink&gt;]. Against 350 pneumococcal isolates resistant (n = 200) and susceptible (n = 150) to various drug classes, daptomycin MIC50 and MIC90 values for all strains were 0.25 microg/ml (range 0.06 to 1 microg/mL), demonstrating the agent to be unaffected by mechanisms that confer resistance to beta-lactams, macrolides, &lt;ulink linkID="44370" linkType="Drug"&gt;clindamycin&lt;/ulink&gt;, streptogramins, fluoroquinolones, and sulfonamides [&lt;ulink linkID="464543" linkType="Reference"&gt;464543&lt;/ulink&gt;]. Daptomycin displayed consistent activity against emerging Gram-positive pathogens non-susceptible to linezolid and &lt;ulink linkID="4275" linkType="Drug"&gt;quinupristin + dalfopristin&lt;/ulink&gt;  [&lt;ulink linkID="464544" linkType="Reference"&gt;464544&lt;/ulink&gt;], [&lt;ulink linkID="464546" linkType="Reference"&gt;464546&lt;/ulink&gt;]. Of 300 Gram-positive pathogens tested, including 128 vancomycin-resistant, 25 susceptible and 10 intermediate enterococci, 298 were susceptible to daptomycin; one VRE and one vancomycin-intermediate enterococci remained unsusceptible [&lt;ulink linkID="464545" linkType="Reference"&gt;464545&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2002,  data were presented at the 12th ECCMID meeting in Milan, Italy. Laboratory studies have shown that mutational resistance to daptomycin was very rare in staphylococci and enterococci. After a 21 days of serial passage in increasing concentrations of daptomycin an isolate of S aureus had MIC90 values of 8 - 32 mg/l, however isolate with MIC90 values in excess of 12.5 mg/l exhibited significant growth impairments. Daptomycin showed rapid in vitro bactericidal activity in a dose-dependent manner, with linear pharmacokinetics in vivo. The half-life of the drug is 9 h with 92% protein binding. Pharmacokinetic studies in volunteers receiving 4 or 6 mg/kg iv qd for 7 days showed serum levels were in the range of 50 to 120 mg/l. In volunteers receiving 4 mg/kg, the Cmax value was 57.7 mg/l and the AUC value was 494 mg h/l while the corresponding values for volunteers receiving 6 mg/kg were 98 mg/l and 747 mg h/l, respectively [&lt;ulink linkID="451297" linkType="Reference"&gt;451297&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2001, preclinical data were presented at the 41st ICAAC meeting in Chicago, IL. In vitro data revealed daptomycin to be active against 25 strains of staphylococci with MIC values in the range 0.25 to 1 microg/ml [&lt;ulink linkID="421494" linkType="Reference"&gt;421494&lt;/ulink&gt;]. The in vitro susceptibility of various microorganisms to daptomycin was evaluated against several strains of staphylococci: US isolates of oxacillin resistant S aureus and coagulase negative staphylococci [&lt;ulink linkID="421498" linkType="Reference"&gt;421498&lt;/ulink&gt;]; European Gram-positive cocci [&lt;ulink linkID="421496" linkType="Reference"&gt;421496&lt;/ulink&gt;]; US clinical streptococci isolates [&lt;ulink linkID="421500" linkType="Reference"&gt;421500&lt;/ulink&gt;]; 338 gram-positive anaerobes and Corynebacteria [&lt;ulink linkID="421501" linkType="Reference"&gt;421501&lt;/ulink&gt;]; NCCLS and BCAS standard type organisms [&lt;ulink linkID="421502" linkType="Reference"&gt;421502&lt;/ulink&gt;]; and S aureus and enterococci in combination with gentamicin to determine any synergistic effects [&lt;ulink linkID="421503" linkType="Reference"&gt;421503&lt;/ulink&gt;]. Activity was also displayed against vancomycin-resistant and multidrug-resistant enterococci species [&lt;ulink linkID="421497" linkType="Reference"&gt;421497&lt;/ulink&gt;]. In a rodent model of aortic valve MRSA endocarditis, daptomycin monotherapy produced a superior bacteriological response than vancomycin, with a significant difference seen at the 40 mg/kg daptomycin dose. A combination of sc daptomycin (40 mg/kg) and im rifampin (25 mg/kg) significantly reduced bacterial vegetation titers compared to daptomycin alone and was comparable to the combination of vancomycin and rifampin [&lt;ulink linkID="421381" linkType="Reference"&gt;421381&lt;/ulink&gt;]. In a rodent model of experimental foreign body infection due to S aureus, daptomycin 30 mg/kg/day was at least equivalent to vancomycin 50 mg/kg bid. Daptomycin did exhibit better bactericidal activity than vancomycin on bacteria grown in vitro or removed from infected fluids [&lt;ulink linkID="421384" linkType="Reference"&gt;421384&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Also in December 2001 at the 41st ICAAC meeting, results from a study of the activity of daptomycin in growth media at 35 and 75 mg/l of Ca2+ compared to that of linezolid against isolates of VRE, MRSA and glycopeptide intermediate-resistant S aureus (GISA) was reported. Daptomycin activity at 48 h was superior to that of linezolid against all isolates tested with the exception of GISA. Ca2+ concentration appeared to have a greater impact on the activity of daptomycin against Enterococcus compared to S aureus [&lt;ulink linkID="421756" linkType="Reference"&gt;421756&lt;/ulink&gt;]. It was suggested that this calcium dependence resulted from an increase in the effective hydrophobicity of daptomycin, which facilitates further interaction of daptomycin with the target lipid bilayers [&lt;ulink linkID="421633" linkType="Reference"&gt;421633&lt;/ulink&gt;]. In an electrophysiological membrane study, daptomycin was shown to gradually and dose-dependently dissipate the membrane potential, which was accompanied by a loss in cell viability [&lt;ulink linkID="421632" linkType="Reference"&gt;421632&lt;/ulink&gt;]. Inhibition of lipoteichoic acid was not part of the mechanism of daptomycin's antibacterial action in S aureus [&lt;ulink linkID="421634" linkType="Reference"&gt;421634&lt;/ulink&gt;]. Resistance to daptomycin in S aureus was associated with diminished drug binding, which may have been related to the loss of a 79 kDa cytoplasmic membrane protein [&lt;ulink linkID="421635" linkType="Reference"&gt;421635&lt;/ulink&gt;]. In a murine thigh model of MSSA and MRSA infection, the activity of daptomycin was compared to that of naficillin, linezolid and vancomycin, alone and in combination with each other. Daptomycin 200 mg/kg bid administered alone and the combination of naficillin 300 mg qid and vancomycin 100 mg qid resulted in greater killing of MSSA, whilst daptomycin gave the best killing of MRSA. No antagonism was seen with any of the combinations [&lt;ulink linkID="421807" linkType="Reference"&gt;421807&lt;/ulink&gt;]. Daptomycin showed potent activity against clinical MRSA isolates. An AUC/MIC ratio of 189 produced an optimal kill ratio for MRSA in pharmacodynamic models. Based on a Monte Carlo prediction model doses of 4, 6 and 8 mg/kg should provide adequate coverage for most MRSA [&lt;ulink linkID="422076" linkType="Reference"&gt;422076&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2001, data presented at the 11th European Congress on Clinical Microbiology and Infectious Diseases in Istanbul, Turkey, showed that daptomycin has good activity against a range of staphylococci, with MIC90 values of 0.5 mg/l. Activity was retained against VISA and MRSA strains. Activity against Streptococcus pneumoniae (MIC90 = 0.25 mg/l) and Streptococcus pyogenes (MIC90 = 0.06 mg/l) was also good. A notable feature of the compound was its activity against enterococci, as it is active against vancomycin-resistant E faecalis and E faecium [&lt;ulink linkID="406671" linkType="Reference"&gt;406671&lt;/ulink&gt;]. Daptomycin was as active as vancomycin and linezolid  against tested enterococci [&lt;ulink linkID="416901" linkType="Reference"&gt;416901&lt;/ulink&gt;]. Daptomycin MIC values determined by NCCLS broth microdilution method and E-test for a total of 195 Gram-positive bacteria showed mean MIC values of 0.46 and 0.73 microg/ml, respectively [&lt;ulink linkID="417299" linkType="Reference"&gt;417299&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2001, data on daptomycin were presented at the 5th International Summit on Antibacterial Drug Discovery and Development, in Princeton, NJ. Efficacy and safety studies against Gram-positive bacteria in animals suggested that qd dosing is appropriate in humans [&lt;ulink linkID="404744" linkType="Reference"&gt;404744&lt;/ulink&gt;]. In September 2000, data on daptomycin were presented at the 40th ICAAC meeting in Toronto, Canada. Data from in vitro tests with 255 clinical isolates and 275 Gram-positive aerobic and anaerobic isolates showed that daptomycin had excellent activity against all strains including MRSA and VRE [&lt;ulink linkID="383248" linkType="Reference"&gt;383248&lt;/ulink&gt;], [&lt;ulink linkID="383257" linkType="Reference"&gt;383257&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2000, results of a completed study evaluating the activity of daptomycin versus vancomycin in the treatment of both verb and MRSA in an in vitro model designed to simulate the growth of bacteria on cardiac tissue in patients suffering from endocarditis were presented at the 36th ASCO meeting in New Orleans, LA. The antibiotics were administered at doses that simulated qd dosing of daptomycin at either 6 or 10 mg/kg and 1 g bid dosing of vancomycin. The results demonstrated that the qd daptomycin versus vancomycin achieved highly significant 99.9% kill of verb and MRSA at 8 h and that daptomycin had significant bactericidal activity still evident at 72 h. Vancomycin had no effect on verb, and demonstrated a static effect on MRSA, with a 1.5 log reduction at 72 h versus a 5.0 to 5.6 log reduction by daptomycin at 72 h [&lt;ulink linkID="367769" linkType="Reference"&gt;367769&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Also in May 2000, in vitro data examining the activity of daptomycin against 2803 Gram-positive clinical isolates were reported. Daptomycin was shown to be active against a variety of vancomycin-R and vancomycin-S strains of enterococci as well as all species of staphylococci and streptococci [&lt;ulink linkID="369177" linkType="Reference"&gt;369177&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 1998, data concerning the antibiotic efficacy of daptomycin were presented at the 38th ICAAC meeting in San Diego, CA. These data showed that daptomycin has potent bactericidal activity against a variety of Gram-positive bacteria, including antibiotic resistant bacteria in vitro, and that in vivo, daptomycin was effective at treating mice that had a lethal infection of VRE. Additional in vitro studies showed that spontaneous rates of resistance to daptomycin were low [&lt;ulink linkID="299470" linkType="Reference"&gt;299470&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Data from studies conducted at the CDC have demonstrated daptomycin's activity against VISA strains  [&lt;ulink linkID="280333" linkType="Reference"&gt;280333&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Daptomycin is a cyclic lipopeptide antibiotic derived from Streptomyces roseosporus which appears to act by disrupting multiple aspects of bacterial plasma membrane functions, including inhibition of peptidoglycan synthesis, inhibition of lipoteichoic acid synthesis and dissipation of bacterial membrane potential [&lt;ulink linkID="335865" linkType="Reference"&gt;335865&lt;/ulink&gt;]. Time-kill studies using fixed antibiotic concentration have indicated that daptomycin is bactericidal against VRSA strains [&lt;ulink linkID="331023" linkType="Reference"&gt;331023&lt;/ulink&gt;]. Daptomycin produces a concentration- and time-dependent post-antibiotic effect, regrowth times and sub-MIC effects [&lt;ulink linkID="335865" linkType="Reference"&gt;335865&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;By February 2012, Cubist had entered into a manufacturing and supply agreement with Hospira, under which Hospira would convert the API into the finished product [&lt;ulink linkID="1268989" linkType="Reference"&gt;1268989&lt;/ulink&gt;]. In February 2013, Cubist stated that it also had an agreement with &lt;ulink linkID="1061541" linkType="Company"&gt;Oso Biopharmaceuticals Manufacturing&lt;/ulink&gt; to provide fill-finish, packaging and labeling services, and with a third-party manufacturer to package and label the finished product produced by Hospira. At that time, Cubist planned to establish an additional third-party manufacturer of the finished product in 2013 [&lt;ulink linkID="1392842" linkType="Reference"&gt;1392842&lt;/ulink&gt;]. In January 2014, the company expected to have  a third fill/finish contract  manufacturing organization  approved for the manufacture of the drug by the end of that year [&lt;ulink linkID="1518567" linkType="Reference"&gt;1518567&lt;/ulink&gt;]. In February 2014, Cubist did not comment on establishing another third-party manufacturer of the finished product and noted that it had the two contracts with Oso and Hospira [&lt;ulink linkID="1529582" linkType="Reference"&gt;1529582&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2005, Cubist  received FDA approval for commercial production of daptomycin at a second bulk drug facility, in Agnani, Italy. The facility was to operated by &lt;ulink linkID="21883" linkType="Company"&gt;ACS Dobfar SpA&lt;/ulink&gt; [&lt;ulink linkID="586562" linkType="Reference"&gt;586562&lt;/ulink&gt;]. In November 2009, the agreement was amended, including  amendments related to improvement and expansion of the facility   [&lt;ulink linkID="1268989" linkType="Reference"&gt;1268989&lt;/ulink&gt;]. By January 2011, the agreement was due to expire in December 2015, with an option to extend the agreement by 2-year periods, subject to certain undisclosed conditions [&lt;ulink linkID="1172820" linkType="Reference"&gt;1172820&lt;/ulink&gt;]. In February 2012, Cubist reported that the manufacturing facility had been expanded and had undergone certain improvements to increase production capacity in 2011 [&lt;ulink linkID="1268989" linkType="Reference"&gt;1268989&lt;/ulink&gt;]. In February 2013, Cubist stated that the term of the agreement could be extended by an additional 2 years after the initial 2-year extension [&lt;ulink linkID="1392842" linkType="Reference"&gt;1392842&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2004, Cubist entered into a manufacture and supply agreement with &lt;ulink linkID="19700" linkType="Company"&gt;Cardinal Health&lt;/ulink&gt;. By February 2012, Oso Biopharmaceuticals was 'successor-in-interest' to the agreement [&lt;ulink linkID="1268989" linkType="Reference"&gt;1268989&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Cubist and Emisphere Technologies signed an R&amp;amp;D collaboration in November 2000, to use Emisphere's oral drug delivery technology for daptomycin [&lt;ulink linkID="388681" linkType="Reference"&gt;388681&lt;/ulink&gt;], [&lt;ulink linkID="399219" linkType="Reference"&gt;399219&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;&lt;subtitle&gt;Lakshmi P Kotra, &lt;ulink linkType="Company" linkID="20702"&gt;Wayne State University&lt;/ulink&gt;, Detroit, MI, USA&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;8 January 2000&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;In the late 20th century the prevalence of infections caused by resistant bacteria, especially Gram-positive bacteria, has risen seriously, rendering the majority of antimicrobial drugs either less effective or ineffective against many important bacterial infections [&lt;ulink linkType="reference" linkID="356071"&gt;356071&lt;/ulink&gt;]. Resistance problems may be mitigated in several ways such as the containment of the resistant strains by judicious use of antimicrobials or controlling the spread of resistant bacteria, as suggested by peers in the field [&lt;ulink linkType="reference" linkID="356072"&gt;356072&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="356074"&gt;356074&lt;/ulink&gt;]. However, it is also essential that new therapeutic agents with novel mechanisms of action, perhaps with multiple mechanisms of action, be developed to treat the infections caused by the drug-resistant bacterial strains.&lt;/para&gt;&lt;para&gt; &lt;ulink linkType="Drug" linkID="2911"&gt;Daptomycin&lt;/ulink&gt; (LY-146032, A-21978C), a cyclic lipopeptide antibiotic, was identified as a potent antibacterial agent against Gram-positive bacteria by scientists at Eli Lilly &amp;amp; Company [&lt;ulink linkType="reference" linkID="82271"&gt;82271&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="278621"&gt;278621&lt;/ulink&gt;]. This compound was isolated as a fermentation product from Streptomyces roseosporus and exerts its antibacterial activity by disrupting multiple aspects of the bacterial membrane function [&lt;ulink linkType="reference" linkID="335865"&gt;335865&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="2911"&gt;Daptomycin&lt;/ulink&gt; shows good antimicrobial activity against most clinically important Gram-positive species, and holds the promise of becoming a useful drug. &lt;/para&gt;&lt;para&gt;In 1997, Cubist Pharmaceuticals acquired the license for the development of &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; and they are currently developing it for the intravenous treatment of patients with serious Gram-positive infections, including those caused by drug-resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) and &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt;-resistant enterococci (VRE). &lt;ulink linkType="Drug" linkID="2911"&gt;Daptomycin&lt;/ulink&gt; is currently undergoing phase II/III clinical evaluation and it is expected to be launched in 2001 to 2002 [&lt;ulink linkType="reference" linkID="341469"&gt;341469&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;The acidic lipopeptide antibiotic complex A-21978C consists of the major components C1, C2 and C3 [&lt;ulink linkType="reference" linkID="82271"&gt;82271&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="356073"&gt;356073&lt;/ulink&gt;] (vide supra). These three components have, respectively, 11, 12 and 13 carbon atoms in the branched fatty acyl chain that is attached to the N-terminus of the peptide nucleus. The fatty acyl chain length is an important structural determinant of the acute toxicity caused by these compounds [&lt;ulink linkType="reference" linkID="82271"&gt;82271&lt;/ulink&gt;]. Several analogs with various lengths of fatty acyl chains were synthesized using enzymatic and chemical modification methods, among them the n-decanoyl analog of A-21978C was the least acutely toxic to mice at doses up to 1000 mg/kg [&lt;ulink linkType="reference" linkID="82271"&gt;82271&lt;/ulink&gt;]. This compound was later called &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt;. &lt;/para&gt;&lt;para&gt;Recently, the &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; biosynthetic gene cluster in S roseosporus was mapped by using a combination of cloning, transposon and insertional mutagenesis, and sequencing techniques [&lt;ulink linkType="reference" linkID="278621"&gt;278621&lt;/ulink&gt;]. This gene cluster spans at least 50 kb, and is located at about 400 to 500 kb from one end of the linear chromosome (approximately 7100 kb) of the bacteria.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;Numerous studies of &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; demonstrated that its spectrum of activity includes most Gram-positive pathogens. The MIC values against these species, including resistant organisms, are relatively low, ie, 0.06 to 2.0 microg/ml [&lt;ulink linkType="reference" linkID="335865"&gt;335865&lt;/ulink&gt;]. Activity is specific to Gram-positive bacteria and no antibacterial activity was reported against Gram-negative bacteria. In vitro studies performed during the 1980s and 1990s showed that &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; inhibits methicillin-susceptible and -resistant S aureus, S epidermidis, S pneumoniae, &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt;-susceptible and -resistant enterococci, C difficile and Corynebacterium sp, among others. In general, &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; showed more potent bactericidal activity in vitro against various species of bacteria than &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="12927"&gt;teicoplanin&lt;/ulink&gt; and several penicillin antibiotics. Several investigators have demonstrated that the antibiotic activity of &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; depends on the presence of physiological concentrations of Ca2+ [&lt;ulink linkType="reference" linkID="25042"&gt;25042&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="122729"&gt;122729&lt;/ulink&gt;]. Its bactericidal activity is rapid and concentration-dependent, as evidenced by in vitro broth microdilution techniques and time-kill kinetics [&lt;ulink linkType="reference" linkID="25042"&gt;25042&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="79648"&gt;79648&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="116465"&gt;116465&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="335865"&gt;335865&lt;/ulink&gt;]. It should be noted that the initial kill-rates of &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; against S aureus and E faecalis are 6- to 24-times faster than those of &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="335865"&gt;335865&lt;/ulink&gt;] at 4- to 8-times MIC concentrations of &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt;. &lt;/para&gt;&lt;para&gt; &lt;ulink linkType="Drug" linkID="2911"&gt;Daptomycin&lt;/ulink&gt;'s post-antibiotic effect and the sub-MIC effects are also suggestive of its potential for effective treatment of bacterial infections. &lt;ulink linkType="Drug" linkID="2911"&gt;Daptomycin&lt;/ulink&gt; exhibits a concentration-dependent post-antibiotic effect in vivo for up to 10.9 h against S aureus and S pneumoniae [&lt;ulink linkType="reference" linkID="342356"&gt;342356&lt;/ulink&gt;], these data are consistent with those obtained in vitro [&lt;ulink linkType="reference" linkID="24992"&gt;24992&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="25042"&gt;25042&lt;/ulink&gt;]. Although sub-MIC concentrations did not completely inhibit the growth of the S aureus, these concentrations led to significant bacterial killing by enhancing the bacterial susceptibility to the cellular and host defense systems [&lt;ulink linkType="reference" linkID="24940"&gt;24940&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The emergence of resistance to &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; is very uncommon, based on the currently available data. In a recent study, when spontaneous resistance was assessed at 8-times the MIC, the incidence of &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; resistance was below detectable levels, ie, &amp;lt; 10(-10) for S aureus, &amp;lt; 10(-9) for S epidermidis, E faecalis, E faecium and &amp;lt; 10(-6) for S pneumoniae [&lt;ulink linkType="reference" linkID="307290"&gt;307290&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="335865"&gt;335865&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="2911"&gt;Daptomycin&lt;/ulink&gt;-resistant strains were generated by serial passage of organisms starting at sub-MIC concentrations [&lt;ulink linkType="reference" linkID="307290"&gt;307290&lt;/ulink&gt;]. In an earlier investigation, serial passages also resulted in &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt;-resistant mutants; limited cross-resistance was evident in strains with stable resistance to &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; or to other selected antibiotics, ie, &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="12927"&gt;teicoplanin&lt;/ulink&gt;, cefamandole or &lt;ulink linkType="Drug" linkID="44438"&gt;ciprofloxacin&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="77555"&gt;77555&lt;/ulink&gt;]. In phase II clinical trials, only one resistant isolate with 8-times the MIC of the original MRSA bacteria was obtained during the treatment of 169 patients receiving &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="335865"&gt;335865&lt;/ulink&gt;]. Thus, it appears that spontaneous resistance to &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; occurs only at a very low frequency. On the other hand, the resistant strains of S aureus and E faecalis had normal growth and virulence [&lt;ulink linkType="reference" linkID="335865"&gt;335865&lt;/ulink&gt;] cautioning that &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt;-resistant mutants could spread. However, high level &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; resistance has not been detected even using mutagenic assays. No additional data are available on the molecular mechanisms responsible for the observed resistance in various strains. &lt;/para&gt;&lt;para&gt; &lt;ulink linkType="Drug" linkID="2911"&gt;Daptomycin&lt;/ulink&gt; has been tested extensively in several animal model systems in vivo and has demonstrated efficacy in the treatment of several Gram-positive infections caused by both antibiotic-resistant and -susceptible strains. In mouse protection studies ED50 values of &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; were &amp;lt;/= 2 mg/kg against S pyogenes, S pneumoniae, methicillin-susceptible S aureus and &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt;-resistant E faecalis, 0.6 to 9.6 mg/kg against MRSA and 14 to 19 mg/kg against methicillin-resistant S epidermidis [&lt;ulink linkType="reference" linkID="335865"&gt;335865&lt;/ulink&gt;]. Additionally, &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; was tested in murine models of enterococcal pyelonephritis [&lt;ulink linkType="reference" linkID="77655"&gt;77655&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="78392"&gt;78392&lt;/ulink&gt;], in hamster models of MRSA pneumonia [&lt;ulink linkType="reference" linkID="80069"&gt;80069&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="84317"&gt;84317&lt;/ulink&gt;], in rat and rabbit models of MRSA osteomyelitis [&lt;ulink linkType="reference" linkID="11395"&gt;11395&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="24978"&gt;24978&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="78953"&gt;78953&lt;/ulink&gt;], in a rabbit model of S aureus ventriculitis [&lt;ulink linkType="reference" linkID="24964"&gt;24964&lt;/ulink&gt;], in a hamster model of C difficile colitis [&lt;ulink linkType="reference" linkID="76633"&gt;76633&lt;/ulink&gt;], in a mouse model of staphylococcal bacteremia [&lt;ulink linkType="reference" linkID="24932"&gt;24932&lt;/ulink&gt;], and in rat and rabbit models of endocarditis caused by staphylococcal, streptococcal and enterococcal strains [&lt;ulink linkType="reference" linkID="11410"&gt;11410&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="24930"&gt;24930&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="24937"&gt;24937&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="24996"&gt;24996&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="78394"&gt;78394&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="80615"&gt;80615&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="115012"&gt;115012&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="119261"&gt;119261&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="156422"&gt;156422&lt;/ulink&gt;]. The efficacy of &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; was typically better than that of &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt; at equivalent dose levels, and comparable at dose levels 4-times lower than those of &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt;. Further, &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; was effective in treating mice that had VRE-induced lethal infections or pyelonephritis [&lt;ulink linkType="reference" linkID="307290"&gt;307290&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="342351"&gt;342351&lt;/ulink&gt;]. Its efficacy appears to be dependent on the ratio of peak serum concentrations or total daily exposure (area under the curve) to MIC [&lt;ulink linkType="reference" linkID="342356"&gt;342356&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="342358"&gt;342358&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="356076"&gt;356076&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;During the initial development of &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt;, multiple mechanisms of antimicrobial action were identified as responsible for its potent bactericidal activity against Gram-positive bacteria. These include the disruption of membrane potential leading to the inhibition of amino acid transport, inhibition of lipoteichoic acid synthesis and the inhibition of peptidoglycan synthesis [&lt;ulink linkType="reference" linkID="24954"&gt;24954&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="25031"&gt;25031&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="25039"&gt;25039&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="76632"&gt;76632&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="123782"&gt;123782&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="188486"&gt;188486&lt;/ulink&gt;]. In biochemical studies, it was concluded that &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; inhibited the formation of UDP-N-acetyl-muramyl peptide intermediates, which are utilized in peptidoglycan biosynthesis using S aureus as a model system [&lt;ulink linkType="reference" linkID="76632"&gt;76632&lt;/ulink&gt;]. In enterococci and Bacillus subtilis, the synthesis of lipoteichoic acid and teichoic acid was inhibited by &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; thus directly disabling one of the bacterial virulence mechanisms [&lt;ulink linkType="reference" linkID="24954"&gt;24954&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="123782"&gt;123782&lt;/ulink&gt;]. In other studies, &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; appeared to disrupt the membrane potential in bacteria leading to the inhibition of amino acid transport across the membrane. The effect on membrane potential was cited as the cause for its inhibitory effects on macromolecular biosynthesis [&lt;ulink linkType="reference" linkID="25031"&gt;25031&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="25039"&gt;25039&lt;/ulink&gt;]. These studies identified possible and multiple modes of action of &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; on the Gram-positive bacteria, although the precise mechanism of action is not yet completely understood [&lt;ulink linkType="reference" linkID="335865"&gt;335865&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity &lt;/subtitle&gt;During repeated-dose animal studies, &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; administration was associated with dose-related skeletal muscle, peripheral nerve, renal and gastrointestinal toxicities. In rats and dogs, at doses &gt;/= 25 and 10 mg/kg, respectively, adverse effects on skeletal muscle were observed [&lt;ulink linkType="reference" linkID="335865"&gt;335865&lt;/ulink&gt;]. The muscle effects were characterized by myopathy of the skeletal muscle (minimal degenerative changes at 25 and 10 mg/kg, in rats and dogs, respectively), increased creatinine phosphokinase (CPK) levels and the loss of muscular function (at the highest doses). No cellular necrosis was apparent in any of the affected skeletal muscle tissue, and there were no adverse effects on either cardiac or smooth muscle. Peripheral neuropathy, characterized by axonal degeneration, occurred at dose levels  approximately 4-times higher than those resulting in myopathy. In rats, renal toxicity, characterized by degeneration of tubular epithelium, increased kidney weight and urinary protein excretion, decreased renal cortex transport and increased creatinine, was observed within the dose range of 10 to 150 mg/kg. In rats, &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; resulted in dose-dependent and reversible loss of renal cells, and electron microscopy showed histopathological changes in the kidneys [&lt;ulink linkType="reference" linkID="24955"&gt;24955&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="2911"&gt;Daptomycin&lt;/ulink&gt; administration to rats led to gastrointestinal changes and a slight decrease in body weight and food consumption, presumably related to antimicrobial effects on gut flora. These effects were observed only at high doses for extended treatment. Renal toxicity appears to be species specific because this effect was not observed in dogs up to highest dose level tested, ie, 75 mg/kg [&lt;ulink linkType="reference" linkID="335865"&gt;335865&lt;/ulink&gt;]. In dogs, studies showed that once-daily administration of &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; was associated with less skeletal muscle toxicity than that with the same total daily dose administered on a fractionated schedule [&lt;ulink linkType="reference" linkID="321595"&gt;321595&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="335865"&gt;335865&lt;/ulink&gt;]. All the toxic manifestations were reversible upon termination of the drug treatment. Monkeys did not exhibit any of the above toxicities up to a dose level of 10 mg/kg [&lt;ulink linkType="reference" linkID="335865"&gt;335865&lt;/ulink&gt;], perhaps due to the low doses. From these data, it appears that the clinically relevant toxicities associated with &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; are limited to skeletal muscle effects and, at higher dose levels, peripheral nerve effects.&lt;/para&gt;&lt;para&gt; &lt;ulink linkType="Drug" linkID="2911"&gt;Daptomycin&lt;/ulink&gt; did not affect any other organ systems adversely in rats, dogs and monkeys including the cardiovascular system, respiratory system and reproductive system. There was also no observed developmental toxicity, mutagenic potential, local injection site irritation or ototoxicity associated with &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; treatment in animals [&lt;ulink linkType="reference" linkID="335865"&gt;335865&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism&lt;/subtitle&gt;Single-dose pharmacokinetic studies were performed in healthy volunteers. &lt;ulink linkType="Drug" linkID="2911"&gt;Daptomycin&lt;/ulink&gt; showed linear pharmacokinetics in the dose range of 0.5 to 6 mg/kg in this study, with a half-life of 8.5 h (range 5.78 to 11.18 h) [&lt;ulink linkType="reference" linkID="25020"&gt;25020&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="335865"&gt;335865&lt;/ulink&gt;]. The plasma clearance rate and volume of distribution were low (7 to 15 ml/h/kg and 0.1 to 0.15 l/kg, respectively), which may be due in part to the high plasma protein binding of &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; (88 to 94%) [&lt;ulink linkType="reference" linkID="25032"&gt;25032&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="146790"&gt;146790&lt;/ulink&gt;] and its inability to cross cell membranes [&lt;ulink linkType="reference" linkID="24954"&gt;24954&lt;/ulink&gt;]. The majority of &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; (78% of the dose) was excreted via urine [&lt;ulink linkType="reference" linkID="25020"&gt;25020&lt;/ulink&gt;]. Although urine analysis indicated that there were minor metabolites, plasma analysis showed the presence of &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; alone without any metabolites [&lt;ulink linkType="reference" linkID="358984"&gt;358984&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;In the late 1980s and early 1990s, 19 phase I and two phase II clinical trials of &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; were conducted by Eli Lilly &amp;amp; Company. Eli Lilly suspended the development of &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; in 1991 and Cubist Pharmaceuticals acquired exclusive licensing rights to &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; in 1997 [&lt;ulink linkType="reference" linkID="268910"&gt;268910&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I/II&lt;/subtitle&gt;In a study in healthy volunteers, antibacterial activities against S aureus strain 2679, methicillin-resistant S aureus and E faecalis were observed for at least 6 h in serum after the administration of a single 4 or 6 mg/kg dose [&lt;ulink linkType="reference" linkID="25020"&gt;25020&lt;/ulink&gt;]. Although the authors conclude that &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; may not be suitable for the treatment of deep-seated infections due to its low volume of distribution, phase II data show that it has efficacy comparable to conventional therapy in the treatment of endocarditis [&lt;ulink linkType="reference" linkID="335865"&gt;335865&lt;/ulink&gt;], and studies to evaluate &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; for deep-seated infections continue. &lt;/para&gt;&lt;para&gt;In a phase II clinical study, pharmacokinetics and bactericidal rates of &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; were determined in patients with Gram-positive (S aureus) endocarditis and bacteremia, and were compared with those of &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="25006"&gt;25006&lt;/ulink&gt;]. The patients received &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; by 30 min iv infusion at a dose of 3 mg/kg every 12 h. In this study, the peak and trough serum concentrations were lower than those reported in healthy volunteers. Further, the volume of distribution and the clearance rate were higher in these patients than in the healthy volunteers, presumably because the patients were intravenous drug abusers. The authors speculate that the altered pharmacokinetic profiles may have contributed to the decreased efficacy of &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; against S aureus endocarditis in these patients [&lt;ulink linkType="reference" linkID="25006"&gt;25006&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The efficacy of &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; was evaluated in two randomized, multicenter, phase II studies conducted by Eli Lilly. Skin and soft tissue infections were cured or improved clinically in 96.6% of cases (29/30 patients) receiving &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; 2 mg/kg every 24 h for up to 25 days [&lt;ulink linkType="reference" linkID="335865"&gt;335865&lt;/ulink&gt;]. In patients with bacteremia, a favorable clinical outcome was observed in 89.5% of the cases (17/19 patients) when treated with &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; at 3 mg/kg every 12 h. This dose regimen resulted in a favorable clinical outcome in the treatment of deep-seated infections, eg, in endocarditis in 64.7% cases (11/17 patients) versus 70% (7/10) with conventional therapy. In each of these clinical studies, the efficacy of &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; was comparable to that of conventional therapy. A favorable outcome was observed in four of nine patients with endocarditis due to S aureus, and in all six patients with endocarditis caused by Enterococcus, Streptococcus or S epidermidis. This response is similar to that observed with conventional therapy [&lt;ulink linkType="reference" linkID="335865"&gt;335865&lt;/ulink&gt;]. The dosing regimens used resulted in peak &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; plasma concentrations of 30 to 70 microg/ml [&lt;ulink linkType="reference" linkID="25006"&gt;25006&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="335865"&gt;335865&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="358984"&gt;358984&lt;/ulink&gt;]. Despite plasma protein binding of approximately 90%, concentrations of unbound &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; in plasma were 3- to 30-times the MIC values for most causative organisms.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;A pivotal phase III trial in complicated skin and soft tissue infections was commenced in March 1999. In July 1999, Cubist filed for approval to commence a second phase III trial in six European Union countries including the UK and Israel. The European trial aims to evaluate the compound in the treatment of complicated skin and soft tissue infections due to Gram-positive bacteria. Future studies will include a phase III pivotal trial in complicated urinary tract infections and a phase II/III trial in endocarditis to be initiated in the year 2000 [&lt;ulink linkType="reference" linkID="280555"&gt;280555&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side Effects and Contraindications&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="2911"&gt;Daptomycin&lt;/ulink&gt; did not show any significant adverse effects that are directly related to the administration of &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; in phase I clinical trials at dose levels up to 3 mg/kg every 12 h. In phase II clinical trials, &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; (2 mg/kg/day) exhibited similar profiles of adverse events to those associated with conventional treatment (&lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt;, semi-synthetic penicillins and beta-lactam agents). Although serious adverse events occurred more frequently in the &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt;-treated groups than in the conventional therapy groups, cause was related to the underlying disease itself and not to drug therapy. &lt;ulink linkType="Drug" linkID="2911"&gt;Daptomycin&lt;/ulink&gt; did not show any significant nephrotoxicity or neurotoxicity at the clinical dose levels tested so far [&lt;ulink linkType="reference" linkID="335865"&gt;335865&lt;/ulink&gt;]. No clinical signs of ototoxicity or histamine release have been observed with &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; administration; hypersensitivity and local irritation have been seen rarely. &lt;/para&gt;&lt;para&gt;Clinical signs of adverse skeletal muscle effects were observed at a higher dose level than those used in phase II clinical trials. In a study with 100 subjects receiving &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; (3 mg/kg every 12 h), one individual exhibited skeletal muscle toxicity indicated by increased levels of CPK, aspartate aminotransferase and &lt;ulink linkType="Company" linkID="18030"&gt;alanine&lt;/ulink&gt; aminotransferase. However, this was reversible upon cessation of the therapy. At a dose level of 4 mg/kg every 12 h, two out of five patients exhibited muscle weakness and myalgia; signs were preceded by elevations in CPK levels and all effects were transient and reversed upon discontinuation of &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; therapy [&lt;ulink linkType="reference" linkID="358984"&gt;358984&lt;/ulink&gt;]. No adverse effects on cardiac and smooth muscles have been observed in any of these clinical studies, consistent with the animal study results. The potential of &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; to cause skeletal muscle effects may be decreased by once-daily administration. Because the major route of elimination is via urine, the &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; dose regimen should be adjusted in patients with renal dysfunction.&lt;/para&gt;&lt;para&gt;Interim results from Cubist's ongoing phase II trial of &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt;, presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in September 1999, showed that the incidence of adverse events in patients receiving &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; at 6 mg/kg every 24 h was comparable to those in patients receiving either &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt; or oxacillin, or lower doses of &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; (4 mg/kg every 24 h or 3 mg/kg every 12 h) [&lt;ulink linkType="reference" linkID="341469"&gt;341469&lt;/ulink&gt;]. Completed phase II studies have shown that &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; is relatively safe and effective against bacteremia and skin and soft tissue infections caused by bacteria such as MRSA, S pyogenes [&lt;ulink linkType="reference" linkID="268910"&gt;268910&lt;/ulink&gt;] and Enterococcus sp [&lt;ulink linkType="reference" linkID="335865"&gt;335865&lt;/ulink&gt;]. Although when administered at 4 mg/kg every 12 h, &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; may lead to adverse skeletal muscle effects, the preliminary human safety profile was favorable in comparison with other major classes of Gram-positive antimicrobials [&lt;ulink linkType="reference" linkID="335865"&gt;335865&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Drug Interactions&lt;/subtitle&gt;Studies on interactions of &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; with other drugs were performed primarily with aminoglycoside antibiotics. In vitro interaction studies with 25 antimicrobials tested against 70 clinical isolates demonstrated indifferent or additive activity; synergism occurred with aminoglycosides against enterococcal organisms [&lt;ulink linkType="reference" linkID="358984"&gt;358984&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="2911"&gt;Daptomycin&lt;/ulink&gt; was co-administered with aminoglycosides such as tobramycin, amikacin and gentamicin to both animals and humans. In rat studies, co-administration of &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; and either tobramycin or gentamicin resulted in decreased aminoglycoside-induced nephrotoxicity [&lt;ulink linkType="reference" linkID="24968"&gt;24968&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="24993"&gt;24993&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="181700"&gt;181700&lt;/ulink&gt;]. In human healthy volunteers, co-administration of &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; and either tobramycin or amikacin did not affect the pharmacokinetic profiles of either &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; or the aminoglycoside [&lt;ulink linkType="reference" linkID="25000"&gt;25000&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="158760"&gt;158760&lt;/ulink&gt;]. In phase II trials, treatment with &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; alone or &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; in combination with tobramycin or gentamicin resulted in similar favorable outcomes. In several patients receiving combination therapy, the favorable clinical outcome was attributable to &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; because the microorganisms were aminoglycoside-resistant (MIC &gt;/= 4 microg/ml) [&lt;ulink linkType="reference" linkID="335865"&gt;335865&lt;/ulink&gt;]. Co-administration of &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; (up to 3 mg/kg every 12 h) and aminoglycosides did not result in nephrotoxicity [&lt;ulink linkType="reference" linkID="335865"&gt;335865&lt;/ulink&gt;]. Thus, it appears that &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; does not have any adverse reactions when co-administered with aminoglycosides at the current clinical dose levels (6 mg/kg/day), and may provide protection against aminoglycoside-induced nephrotoxicity. To date, no notable adverse drug interactions have been reported from patients treated with &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt;. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;In September 1998, data presented at the 38th ICAAC showed that &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; has potent bactericidal activity against most Gram-positive pathogenic bacteria. It was active against resistant bacteria in vitro and was effective in vivo in treating mice with lethal VRE infection. These studies, in essence, concur with the previous studies of the late 1980s and early 1990s. Efficacy studies in animals and humans revealed good potential for the eradication of soft tissue and skin infections and bacteremia caused by S aureus, Streptococcus and Enterococcus. More data are needed, however, to evaluate the efficacy of &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; in the treatment of deep-seated infections. In vitro studies showed that spontaneous rates of resistance to &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; were low [&lt;ulink linkType="reference" linkID="299470"&gt;299470&lt;/ulink&gt;] and the emergence of resistance during clinical trials was rare. In light of its potent bactericidal activity, &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; may be a useful clinical option in the treatment of Gram-positive infections. &lt;/para&gt;&lt;para&gt;The safety profile of &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; appears comparable to or possibly more favorable than that of other antimicrobial agents, however, reversible skeletal muscle effects should be monitored carefully in patients receiving &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; at doses &amp;gt; 6 mg/kg/day and in patients with renal dysfunction. A once-daily dosing regimen is perhaps the key to safe and effective therapy with &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt;. It should also be noted that &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt; has not shown any major drug interactions in the studies performed to date, although more studies are needed in this area. Its neutralizing effect on aminoglycoside-induced nephrotoxicity may be useful in combination therapy.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Acknowledgement&lt;/subtitle&gt;The author would like to express his gratitude to Drs Frederick B Oleson Jr and Francis P Tally for providing up-to-date information and data on &lt;ulink linkType="Drug" linkID="2911"&gt;daptomycin&lt;/ulink&gt;, which was very useful in producing this evaluation.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="29954">TTY Biopharm Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3897">Complicated skin and skin structure infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-05-01T00:00:00.000Z</StatusDate><Source id="1721188" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19858">Sunovion Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1475">Streptococcus pyogenes infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-10-12T00:00:00.000Z</StatusDate><Source id="1139103" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1556">Bacterial endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="GR">Greece</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="GR">Greece</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1475">Streptococcus pyogenes infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1556">Bacterial endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29954">TTY Biopharm Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="138">Gram positive bacterium infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-05-01T00:00:00.000Z</StatusDate><Source id="1721188" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-01-21T00:00:00.000Z</StatusDate><Source id="1627968" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19858">Sunovion Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3897">Complicated skin and skin structure infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-10-12T00:00:00.000Z</StatusDate><Source id="1139103" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="GR">Greece</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1482">Enterococcus faecalis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1267">MRSA infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1556">Bacterial endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19858">Sunovion Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-10-12T00:00:00.000Z</StatusDate><Source id="1139103" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29954">TTY Biopharm Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1556">Bacterial endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-05-01T00:00:00.000Z</StatusDate><Source id="1721188" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1482">Enterococcus faecalis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-01-21T00:00:00.000Z</StatusDate><Source id="1627968" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-01-21T00:00:00.000Z</StatusDate><Source id="1627968" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27398">Kuhnil Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1556">Bacterial endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-12-01T00:00:00.000Z</StatusDate><Source id="1578005" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19858">Sunovion Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-10-12T00:00:00.000Z</StatusDate><Source id="1139103" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3897">Complicated skin and skin structure infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-01-21T00:00:00.000Z</StatusDate><Source id="1627968" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="GR">Greece</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="138">Gram positive bacterium infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29954">TTY Biopharm Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-05-01T00:00:00.000Z</StatusDate><Source id="1721188" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1476">Streptococcus agalactiae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-01-21T00:00:00.000Z</StatusDate><Source id="1627968" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19858">Sunovion Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1476">Streptococcus agalactiae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-10-12T00:00:00.000Z</StatusDate><Source id="1139103" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="312">Streptococcus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-01-21T00:00:00.000Z</StatusDate><Source id="1627968" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1556">Bacterial endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3897">Complicated skin and skin structure infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29954">TTY Biopharm Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-05-01T00:00:00.000Z</StatusDate><Source id="1721188" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-01-21T00:00:00.000Z</StatusDate><Source id="1627968" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27398">Kuhnil Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-12-01T00:00:00.000Z</StatusDate><Source id="1578005" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19858">Sunovion Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-10-12T00:00:00.000Z</StatusDate><Source id="1139103" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24019">MSD Japan</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1267">MRSA infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-09-22T00:00:00.000Z</StatusDate><Source id="1224730" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1475">Streptococcus pyogenes infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-01-21T00:00:00.000Z</StatusDate><Source id="1627968" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19858">Sunovion Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1556">Bacterial endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-10-12T00:00:00.000Z</StatusDate><Source id="1139103" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19858">Sunovion Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1267">MRSA infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-10-12T00:00:00.000Z</StatusDate><Source id="1139103" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="CL">Chile</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3897">Complicated skin and skin structure infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1267">MRSA infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-01-21T00:00:00.000Z</StatusDate><Source id="1627968" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1556">Bacterial endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-01-21T00:00:00.000Z</StatusDate><Source id="1627968" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27398">Kuhnil Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3897">Complicated skin and skin structure infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-12-01T00:00:00.000Z</StatusDate><Source id="1578005" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="GR">Greece</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1476">Streptococcus agalactiae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29943">Medison Pharma Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1482">Enterococcus faecalis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-09-15T00:00:00.000Z</StatusDate><Source id="1130971" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29943">Medison Pharma Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1267">MRSA infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-09-15T00:00:00.000Z</StatusDate><Source id="1130971" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-01-21T00:00:00.000Z</StatusDate><Source id="1627968" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29943">Medison Pharma Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-09-15T00:00:00.000Z</StatusDate><Source id="1130971" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="LI">Liechtenstein</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="LT">Lithuania</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="SK">Slovakia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29943">Medison Pharma Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-09-15T00:00:00.000Z</StatusDate><Source id="1130971" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1556">Bacterial endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3897">Complicated skin and skin structure infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="SK">Slovakia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29943">Medison Pharma Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3897">Complicated skin and skin structure infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-09-15T00:00:00.000Z</StatusDate><Source id="1130971" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="SK">Slovakia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1556">Bacterial endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29943">Medison Pharma Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1476">Streptococcus agalactiae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-09-15T00:00:00.000Z</StatusDate><Source id="1130971" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="NO">Norway</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3897">Complicated skin and skin structure infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29943">Medison Pharma Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="312">Streptococcus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-09-15T00:00:00.000Z</StatusDate><Source id="1130971" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29943">Medison Pharma Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1475">Streptococcus pyogenes infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-09-15T00:00:00.000Z</StatusDate><Source id="1130971" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29943">Medison Pharma Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-09-15T00:00:00.000Z</StatusDate><Source id="1130971" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29943">Medison Pharma Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1556">Bacterial endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-09-15T00:00:00.000Z</StatusDate><Source id="1130971" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="EE">Estonia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3897">Complicated skin and skin structure infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="LT">Lithuania</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="GR">Greece</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1475">Streptococcus pyogenes infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1556">Bacterial endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="FR">France</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1556">Bacterial endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="GR">Greece</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1476">Streptococcus agalactiae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CL">Chile</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3897">Complicated skin and skin structure infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1267">MRSA infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="EE">Estonia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="FR">France</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1556">Bacterial endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="GR">Greece</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="SK">Slovakia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1556">Bacterial endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="ES">Spain</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="GR">Greece</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1482">Enterococcus faecalis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="SK">Slovakia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="SK">Slovakia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1556">Bacterial endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16450">Gilead Sciences Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2002-09-09T00:00:00.000Z</StatusDate><Source id="463376" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="GR">Greece</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="138">Gram positive bacterium infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3897">Complicated skin and skin structure infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3897">Complicated skin and skin structure infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1556">Bacterial endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1135">Osteomyelitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="GT">Guatemala</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1135">Osteomyelitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2002-06-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2002-04-17T00:00:00.000Z</StatusDate><Source id="393026" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1135">Osteomyelitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="XE">South America</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1135">Osteomyelitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1135">Osteomyelitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-08-13T00:00:00.000Z</StatusDate><Source id="439841" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1135">Osteomyelitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="CN">China</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-03-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1135">Osteomyelitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1135">Osteomyelitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-10-03T00:00:00.000Z</StatusDate><Source id="507496" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1997-11-10T00:00:00.000Z</StatusDate><Source id="268910" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-10-03T00:00:00.000Z</StatusDate><Source id="507496" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="24019">MSD Japan</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1267">MRSA infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1204912" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-10-16T00:00:00.000Z</StatusDate><Source id="1050030" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1556">Bacterial endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-10-16T00:00:00.000Z</StatusDate><Source id="1050030" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="FR">France</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1556">Bacterial endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-01-19T00:00:00.000Z</StatusDate><Source id="1348829" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="FR">France</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-01-19T00:00:00.000Z</StatusDate><Source id="1348829" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="ES">Spain</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-03-21T00:00:00.000Z</StatusDate><Source id="1357111" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-01-23T00:00:00.000Z</StatusDate><Source id="646449" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1135">Osteomyelitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-08-26T00:00:00.000Z</StatusDate><Source id="1469277" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1135">Osteomyelitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-26T00:00:00.000Z</StatusDate><Source id="887930" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27398">Kuhnil Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-08-01T00:00:00.000Z</StatusDate><Source id="817990" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27398">Kuhnil Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1556">Bacterial endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-08-01T00:00:00.000Z</StatusDate><Source id="817990" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27398">Kuhnil Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3897">Complicated skin and skin structure infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-08-01T00:00:00.000Z</StatusDate><Source id="817990" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29954">TTY Biopharm Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1556">Bacterial endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-08-01T00:00:00.000Z</StatusDate><Source id="817990" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29954">TTY Biopharm Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-08-01T00:00:00.000Z</StatusDate><Source id="817990" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29954">TTY Biopharm Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3897">Complicated skin and skin structure infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-11-30T00:00:00.000Z</StatusDate><Source id="817990" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29954">TTY Biopharm Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="138">Gram positive bacterium infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-11-30T00:00:00.000Z</StatusDate><Source id="817990" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1135">Osteomyelitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-26T00:00:00.000Z</StatusDate><Source id="887930" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1135">Osteomyelitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-01-29T00:00:00.000Z</StatusDate><Source id="1469277" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1135">Osteomyelitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-01-29T00:00:00.000Z</StatusDate><Source id="1469277" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="GT">Guatemala</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1135">Osteomyelitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-08-26T00:00:00.000Z</StatusDate><Source id="1469277" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-11-04T00:00:00.000Z</StatusDate><Source id="511436" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1267">MRSA infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-11-04T00:00:00.000Z</StatusDate><Source id="511436" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1475">Streptococcus pyogenes infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-11-04T00:00:00.000Z</StatusDate><Source id="511436" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1476">Streptococcus agalactiae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-11-04T00:00:00.000Z</StatusDate><Source id="511436" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="312">Streptococcus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-11-04T00:00:00.000Z</StatusDate><Source id="511436" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1482">Enterococcus faecalis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-11-04T00:00:00.000Z</StatusDate><Source id="511436" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-05-25T00:00:00.000Z</StatusDate><Source id="669778" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1556">Bacterial endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-05-25T00:00:00.000Z</StatusDate><Source id="669778" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-11-04T00:00:00.000Z</StatusDate><Source id="511436" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-08-31T00:00:00.000Z</StatusDate><Source id="574322" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-01-23T00:00:00.000Z</StatusDate><Source id="646449" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-04-19T00:00:00.000Z</StatusDate><Source id="662631" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><Source id="1357111" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-09-13T00:00:00.000Z</StatusDate><Source id="829842" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1556">Bacterial endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-09-13T00:00:00.000Z</StatusDate><Source id="829842" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-09-13T00:00:00.000Z</StatusDate><Source id="829842" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1267">MRSA infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-09-13T00:00:00.000Z</StatusDate><Source id="829842" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><Source id="1450511" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-07-17T00:00:00.000Z</StatusDate><Source id="678795" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-07-17T00:00:00.000Z</StatusDate><Source id="678795" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-03-19T00:00:00.000Z</StatusDate><Source id="1348829" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1556">Bacterial endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-03-19T00:00:00.000Z</StatusDate><Source id="1348829" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-11-20T00:00:00.000Z</StatusDate><Source id="1422826" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="GR">Greece</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="138">Gram positive bacterium infection</Indication><Source id="1438015" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="GR">Greece</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1475">Streptococcus pyogenes infection</Indication><Source id="1438015" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="GR">Greece</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1476">Streptococcus agalactiae infection</Indication><Source id="1438015" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="GR">Greece</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1482">Enterococcus faecalis infection</Indication><Source id="1438015" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="GR">Greece</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><Source id="1438015" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="LI">Liechtenstein</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-01-23T00:00:00.000Z</StatusDate><Source id="646449" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="NO">Norway</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-01-23T00:00:00.000Z</StatusDate><Source id="646449" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-09-04T00:00:00.000Z</StatusDate><Source id="828584" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1556">Bacterial endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-09-04T00:00:00.000Z</StatusDate><Source id="828584" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-09-04T00:00:00.000Z</StatusDate><Source id="828584" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="SK">Slovakia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1556">Bacterial endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-01-19T00:00:00.000Z</StatusDate><Source id="1467794" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="SK">Slovakia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-01-19T00:00:00.000Z</StatusDate><Source id="1467794" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="SK">Slovakia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-01-19T00:00:00.000Z</StatusDate><Source id="1467794" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="EE">Estonia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-01-19T00:00:00.000Z</StatusDate><Source id="1459778" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-01-23T00:00:00.000Z</StatusDate><Source id="646449" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="LT">Lithuania</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-01-19T00:00:00.000Z</StatusDate><Source id="1464029" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1556">Bacterial endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-05-02T00:00:00.000Z</StatusDate><Source id="1286096" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-05-02T00:00:00.000Z</StatusDate><Source id="1286096" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-05-02T00:00:00.000Z</StatusDate><Source id="1286096" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CL">Chile</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-04-30T00:00:00.000Z</StatusDate><Source id="1351928" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-01-15T00:00:00.000Z</StatusDate><Source id="1647989" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1130851" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3897">Complicated skin and skin structure infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1130851" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1556">Bacterial endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1130851" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1130851" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1556">Bacterial endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3897">Complicated skin and skin structure infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3897">Complicated skin and skin structure infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-09-12T00:00:00.000Z</StatusDate><Source id="504729" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3897">Complicated skin and skin structure infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-11-04T00:00:00.000Z</StatusDate><Source id="511436" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3897">Complicated skin and skin structure infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2002-12-20T00:00:00.000Z</StatusDate><Source id="474813" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3897">Complicated skin and skin structure infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-09-04T00:00:00.000Z</StatusDate><Source id="828584" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CN">China</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3897">Complicated skin and skin structure infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-09-30T00:00:00.000Z</StatusDate><Source id="1396542" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3897">Complicated skin and skin structure infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-12-02T00:00:00.000Z</StatusDate><Source id="574069" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="LI">Liechtenstein</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3897">Complicated skin and skin structure infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-01-23T00:00:00.000Z</StatusDate><Source id="646449" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="NO">Norway</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3897">Complicated skin and skin structure infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-01-23T00:00:00.000Z</StatusDate><Source id="646449" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3897">Complicated skin and skin structure infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-01-23T00:00:00.000Z</StatusDate><Source id="646449" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3897">Complicated skin and skin structure infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-01-23T00:00:00.000Z</StatusDate><Source id="646449" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3897">Complicated skin and skin structure infection</Indication><Source id="1450511" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3897">Complicated skin and skin structure infection</Indication><Source id="1357111" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3897">Complicated skin and skin structure infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-07-17T00:00:00.000Z</StatusDate><Source id="678795" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3897">Complicated skin and skin structure infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-07-17T00:00:00.000Z</StatusDate><Source id="678795" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3897">Complicated skin and skin structure infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-11-20T00:00:00.000Z</StatusDate><Source id="1422826" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3897">Complicated skin and skin structure infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-03-01T00:00:00.000Z</StatusDate><Source id="653868" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29723">Sunovion Pharmaceuticals Canada Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3897">Complicated skin and skin structure infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-09-26T00:00:00.000Z</StatusDate><Source id="833172" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29723">Sunovion Pharmaceuticals Canada Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3897">Complicated skin and skin structure infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-12-03T00:00:00.000Z</StatusDate><Source id="1130846" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1135">Osteomyelitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-01-26T00:00:00.000Z</StatusDate><Source id="887930" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2000-12-14T00:00:00.000Z</StatusDate><Source id="393592" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1135">Osteomyelitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-10T00:00:00.000Z</StatusDate><Source id="1721186" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CN">China</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-09-30T00:00:00.000Z</StatusDate><Source id="1396542" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1135">Osteomyelitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-01-21T00:00:00.000Z</StatusDate><Source id="1627968" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1135">Osteomyelitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-01-21T00:00:00.000Z</StatusDate><Source id="1627968" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="GT">Guatemala</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1135">Osteomyelitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-01-21T00:00:00.000Z</StatusDate><Source id="1627968" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1135">Osteomyelitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-03-16T00:00:00.000Z</StatusDate><Source id="1469277" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1135">Osteomyelitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-03-16T00:00:00.000Z</StatusDate><Source id="1469277" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1135">Osteomyelitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-03-16T00:00:00.000Z</StatusDate><Source id="1469277" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1135">Osteomyelitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-03-16T00:00:00.000Z</StatusDate><Source id="1469277" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1135">Osteomyelitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-03-16T00:00:00.000Z</StatusDate><Source id="1469277" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><Source id="181700" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-09-12T00:00:00.000Z</StatusDate><Source id="504729" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-09-12T00:00:00.000Z</StatusDate><Source id="504729" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-09-12T00:00:00.000Z</StatusDate><Source id="504729" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2002-12-20T00:00:00.000Z</StatusDate><Source id="474813" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2002-12-20T00:00:00.000Z</StatusDate><Source id="474813" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2002-12-20T00:00:00.000Z</StatusDate><Source id="474813" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2000-12-14T00:00:00.000Z</StatusDate><Source id="393592" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2000-12-14T00:00:00.000Z</StatusDate><Source id="393592" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-07-01T00:00:00.000Z</StatusDate><Source id="331941" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-03-02T00:00:00.000Z</StatusDate><Source id="316799" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-03-02T00:00:00.000Z</StatusDate><Source id="316799" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1998-02-25T00:00:00.000Z</StatusDate><Source id="268910" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1998-02-25T00:00:00.000Z</StatusDate><Source id="268910" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1997-11-11T00:00:00.000Z</StatusDate><Source id="268910" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1997-11-11T00:00:00.000Z</StatusDate><Source id="268910" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-07-01T00:00:00.000Z</StatusDate><Source id="331941" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-10-03T00:00:00.000Z</StatusDate><Source id="507496" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-10-03T00:00:00.000Z</StatusDate><Source id="507496" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-10-03T00:00:00.000Z</StatusDate><Source id="507496" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2000-12-14T00:00:00.000Z</StatusDate><Source id="393592" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-07-01T00:00:00.000Z</StatusDate><Source id="331941" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-12-02T00:00:00.000Z</StatusDate><Source id="574069" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-12-02T00:00:00.000Z</StatusDate><Source id="574069" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="GB">UK</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-12-02T00:00:00.000Z</StatusDate><Source id="574069" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1556">Bacterial endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-09-05T00:00:00.000Z</StatusDate><Source id="828584" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29723">Sunovion Pharmaceuticals Canada Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-04-06T00:00:00.000Z</StatusDate><Source id="833378" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-10-03T00:00:00.000Z</StatusDate><Source id="507496" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16450">Gilead Sciences Inc</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-01-09T00:00:00.000Z</StatusDate><Source id="395220" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-12-04T00:00:00.000Z</StatusDate><Source id="748062" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24019">MSD Japan</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-03-19T00:00:00.000Z</StatusDate><Source id="777005" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-01-23T00:00:00.000Z</StatusDate><Source id="646449" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29723">Sunovion Pharmaceuticals Canada Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-09-26T00:00:00.000Z</StatusDate><Source id="833172" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29723">Sunovion Pharmaceuticals Canada Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-09-26T00:00:00.000Z</StatusDate><Source id="833172" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29723">Sunovion Pharmaceuticals Canada Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1556">Bacterial endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-09-26T00:00:00.000Z</StatusDate><Source id="833172" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29723">Sunovion Pharmaceuticals Canada Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-09-26T00:00:00.000Z</StatusDate><Source id="833172" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29723">Sunovion Pharmaceuticals Canada Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="138">Gram positive bacterium infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-09-26T00:00:00.000Z</StatusDate><Source id="833172" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2000-10-17T00:00:00.000Z</StatusDate><Source id="393026" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2002-02-13T00:00:00.000Z</StatusDate><Source id="439841" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24019">MSD Japan</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1079416" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29723">Sunovion Pharmaceuticals Canada Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-12-03T00:00:00.000Z</StatusDate><Source id="1130846" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29723">Sunovion Pharmaceuticals Canada Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1267">MRSA infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-12-03T00:00:00.000Z</StatusDate><Source id="1130846" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29723">Sunovion Pharmaceuticals Canada Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1475">Streptococcus pyogenes infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-12-03T00:00:00.000Z</StatusDate><Source id="1130846" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29723">Sunovion Pharmaceuticals Canada Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1476">Streptococcus agalactiae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-12-03T00:00:00.000Z</StatusDate><Source id="1130846" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29723">Sunovion Pharmaceuticals Canada Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1556">Bacterial endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-12-03T00:00:00.000Z</StatusDate><Source id="1130846" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29723">Sunovion Pharmaceuticals Canada Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-12-03T00:00:00.000Z</StatusDate><Source id="1130846" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29723">Sunovion Pharmaceuticals Canada Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-12-03T00:00:00.000Z</StatusDate><Source id="1130846" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24019">MSD Japan</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1267">MRSA infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-09-20T00:00:00.000Z</StatusDate><Source id="1134864" type="SERIAL"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="21697">Cubist Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="1815">Bacterial pneumonia</Indication><AwardedIndication>Treatment of Community-acquired pneumonia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-12-31T00:00:00.000Z</MileStoneDate><Source id="337556" type="SERIAL"></Source></Row><Row><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation><OwnerCompany id="21697">Cubist Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="3897">Complicated skin and skin structure infection</Indication><AwardedIndication>Treatment of complicated skin and skin structure infections (cSSSI) caused by Gram-positive organisms, including both antibiotic-susceptible and -resistant strains of Staphylococcus aureus</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-07-20T00:00:00.000Z</MileStoneDate><Source id="479414" type="PR"></Source></Row></RegulatoryDesignationStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="14190">AstraZeneca plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="16024">Emisphere Technologies Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="16450">Gilead Sciences Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="17810">Eli Lilly &amp; Co</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18077">Merck &amp; Co Inc</Company><CountAsPrincipalActive>9</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>9</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>17</CountTotal></Company><Company><Company id="18767">Pfizer Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="20268">Sumitomo Chemical Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="21199">Albany Molecular Research Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="21883">ACS Dobfar SpA</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="23137">Novartis AG</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="27398">Kuhnil Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="29943">Medison Pharma Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="29954">TTY Biopharm Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="DOL1000090">Royalty Pharma</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="10">Technology - Other Proprietary</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>5</CountActive><CountInactive>0</CountInactive><CountTotal>5</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>6</CountActive><CountInactive>0</CountInactive><CountTotal>6</CountTotal></Type><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>4</CountActive><CountInactive>0</CountInactive><CountTotal>4</CountTotal></Type><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="8">Technology - Delivery/Formulation</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2c1cccc2)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H]3[C@H](OC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC3=O)CCCN)CC(=O)O)C)CC(=O)O)CO)[C@H](C)CC(=O)O)CC(=O)c4ccccc4N)C</Smiles></StructureSmiles><Deals><Deal id="109402" title="AstraZeneca to develop Cubist's daptomycin   "></Deal><Deal id="111917" title="Chiron to develop and commercialize daptomycin from Cubist Pharmaceuticals"></Deal><Deal id="111919" title="Cubist Pharmaceuticals to develop and market Eli Lilly's daptomycin to treat infectious diseases caused by Staphylococcus aureus and enterococci worldwide"></Deal><Deal id="112708" title="Oryx to commercialize Cubist's daptomycin in Canada"></Deal><Deal id="116398" title="Gilead Sciences to market Cubist's daptomycin in Europe         "></Deal><Deal id="116467" title="Merck &amp; Co to develop Cubist Pharmaceuticals' daptomycin in Japan"></Deal><Deal id="118510" title="Cubist to discover and develop lipopeptide derivatives using AMRI's combinatorial biocatalysis technology "></Deal><Deal id="122821" title="Cubist to use Emisphere's oral delivery technology for daptomycin worldwide "></Deal><Deal id="122823" title="Medison Pharma to market Cubist's daptomycin in Israel"></Deal><Deal id="122825" title="TTY Biopharm to market Cubist's daptomycin in Taiwan"></Deal><Deal id="129302" title="ACS Dobfar to supply daptomycin API to Cubist Pharmaceuticals"></Deal><Deal id="134388" title="Royalty Pharma to acquire certain royalties for Lexiscan and Cubicin from an undisclosed company"></Deal><Deal id="148814" title="ACS Dobfar to manufacture and supply API for Cubist's Cubicin  "></Deal><Deal id="148818" title="Hospira to provide fill and finish services to Cubist's Cubicin "></Deal><Deal id="148820" title="Oso Biopharmaceuticals to provide fill-finish, packaging and labeling services for Cubist's Cubicin "></Deal><Deal id="150100" title="Kuhnil to market Cubist's Cubicin in Korea"></Deal><Deal id="183648" title="CUBICIN (daptomycin for injection) in Japan"></Deal><Deal id="187980" title="Hospira to manufacture and supply Cubist' daptomycin against serious gram positive infections "></Deal></Deals><PatentFamilies><PatentFamily id="1003679" number="EP-02149609" title="Improved process for the production of daptomycin"></PatentFamily><PatentFamily id="1028470" number="CN-101724674" title="Method for improving daptomycin output by adding daptomycin synthetic key enzyme cofactor"></PatentFamily><PatentFamily id="1038957" number="CN-102276696" title="Method for purifying daptomycin"></PatentFamily><PatentFamily id="1053045" number="EP-00178152" title="Production of A-21978c derivatives."></PatentFamily><PatentFamily id="1107901" number="CN-101880703" title="Method for fermenting daptomycin by flowingly adding caprate"></PatentFamily><PatentFamily id="1191031" number="WO-2012094671" title="Modular extracorporeal systems and methods for treating blood-borne diseases"></PatentFamily><PatentFamily id="1196950" number="EP-00095295" title="Cyclic peptide derivatives"></PatentFamily><PatentFamily id="1213639" number="WO-02056829" title="Methods For Preparing Purified Daptomycin"></PatentFamily><PatentFamily id="1244423" number="WO-2010029104" title="Use of a pharmaceutical composition for the local treatment of infections, and medical product"></PatentFamily><PatentFamily id="1331329" number="WO-2010147836" title="Combination therapies using antibacterial aminoglycoside compounds"></PatentFamily><PatentFamily id="1336302" number="WO-2010107794" title="Compositions and methods for delivering an agent to a wound"></PatentFamily><PatentFamily id="1390193" number="CN-101830970" title="A purification preparation method of high-purity daptomycin"></PatentFamily><PatentFamily id="1404834" number="WO-2011043788" title="Daptomycin for multiple sclerosis"></PatentFamily><PatentFamily id="1414623" number="CN-102492024" title="Method for extracting daptomycin from ferment solution"></PatentFamily><PatentFamily id="1467667" number="CN-01616083" title="Daptomycin freeze-dried preparation for injection and preparing method"></PatentFamily><PatentFamily id="1491592" number="WO-2011063419" title="Lipopeptide compositions and related methods"></PatentFamily><PatentFamily id="1496314" number="EP-00294990" title="Chromatographic purification process"></PatentFamily><PatentFamily id="1557940" number="HR-20110410" title="Improved process for the production of daptomycin"></PatentFamily><PatentFamily id="1558540" number="CN-102485902" title="A method of producing fermentation daptomycin"></PatentFamily><PatentFamily id="1632660" number="CN-102703551" title="Wherein the first kind of daptomycin fermentation process capric added new method"></PatentFamily><PatentFamily id="1636507" number="KR-2012058790" title="&lt;i&gt;Streptomyces rorze&lt;/i&gt; OSS porous strain with improved daptomycin productivity and the daptomycin manufacturing method using the same."></PatentFamily><PatentFamily id="1751992" number="WO-00153330" title="High purity lipopeptides, lipopeptide micelles and processes for preparing same."></PatentFamily><PatentFamily id="1780695" number="CA-02752784" title="Daptomycin formulation"></PatentFamily><PatentFamily id="1805541" number="WO-00197851" title="Compositions And Methods To Improve The Oral Absorption Of Antimicrobial Agents"></PatentFamily><PatentFamily id="1926946" number="CN-101892287" title="Sifting method for streptomyces roseosporus strain for breeding production of daptomycin and obtained strain"></PatentFamily><PatentFamily id="1953606" number="WO-02059322" title="Compositions And Methods Relating To The Daptomycin Biosynthetic Gene Cluster"></PatentFamily><PatentFamily id="1959469" number="WO-2008042970" title="Chitosan-coated calcium sulfate based medicament delivery system"></PatentFamily><PatentFamily id="1973758" number="WO-2010095953" title="Process for purifying lipopeptides"></PatentFamily><PatentFamily id="1976445" number="WO-2005111222" title="Method for expressing biosynthetic pathways and uses thereof"></PatentFamily><PatentFamily id="1981843" number="WO-2009144739" title="Amorphous daptomycin and a method of purification thereof"></PatentFamily><PatentFamily id="2004614" number="CN-102146414" title="Method for building Streptomyces roseosporus gene engineering bacterium and application thereof"></PatentFamily><PatentFamily id="2014633" number="EP-00386951" title="An improved diluent formulation for daptomycin."></PatentFamily><PatentFamily id="2130145" number="WO-2011035108" title="Formulations of daptomycin"></PatentFamily><PatentFamily id="2206610" number="CN-101824452" title="Batch feeding fermentation method for producing daptomycin from Streptomyces roseosporus efficiently"></PatentFamily><PatentFamily id="222513" number="CN-101899094" title="Preparation method of high-purity daptomycin"></PatentFamily><PatentFamily id="225868" number="CN-102260700" title="Construction method for &lt;i&gt;Streptomyces roseosporus&lt;/i&gt; gene engineering bacteria hp-orf53-55 and application thereof"></PatentFamily><PatentFamily id="2381300" number="CN-102718839" title="A method for separating and purifying daptomycin"></PatentFamily><PatentFamily id="2424938" number="CN-102796680" title="A streptomyces roseosporus and uses the combined precursor production of daptomycin method"></PatentFamily><PatentFamily id="2460105" number="CN-102875652" title="Method for separating and purifying daptomycin"></PatentFamily><PatentFamily id="2508952" number="CN-103006562" title="Daptomycin alcohol substance body preparation"></PatentFamily><PatentFamily id="2509575" number="CN-102993273" title="The use of monodisperse polymethacrylate strong anion exchange chromatography medium purification is daptomycin"></PatentFamily><PatentFamily id="2517536" number="WO-2013059610" title="Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use"></PatentFamily><PatentFamily id="2518991" number="WO-2013063405" title="Methods of treating Gram-negative microbial infections"></PatentFamily><PatentFamily id="2534658" number="CN-102924572" title="Method for preparing high-purity daptomycin"></PatentFamily><PatentFamily id="2554930" number="CN-103159829" title="Extracting method of daptomycin"></PatentFamily><PatentFamily id="2558038" number="WO-2013103801" title="Pharmaceutical spray drying"></PatentFamily><PatentFamily id="2570165" number="CN-102965304" title="Daptomycin high-producing strain and preparation method thereof"></PatentFamily><PatentFamily id="2574500" number="CN-103224547" title="A kind of separate daptomycin purification method"></PatentFamily><PatentFamily id="2631271" number="WO-2013170015" title="Bacteriophage lysin and antibiotic combinations against Gram positive bacteria"></PatentFamily><PatentFamily id="2698938" number="WO-2014041425" title="Daptomycin formulations and uses thereof"></PatentFamily><PatentFamily id="2706132" number="WO-2014045296" title="Improved daptomycin injectable formulation"></PatentFamily><PatentFamily id="2721081" number="CN-103724400" title="One separating and purifying a daptomycin of dehydration method"></PatentFamily><PatentFamily id="2747694" number="CN-103695511" title="One a fermentation production method of daptomycin"></PatentFamily><PatentFamily id="2747696" number="CN-103695509" title="One method a flow adding decyl aldehyde fermentation production of daptomycin"></PatentFamily><PatentFamily id="2758092" number="WO-2014096333" title="Anti-staphylococcal antibodies"></PatentFamily><PatentFamily id="2799224" number="WO-2014142915" title="Methods for producing a biodegradable chitosan composition and uses thereof"></PatentFamily><PatentFamily id="2814637" number="CN-103937694" title="Bacterial strain and screening method of high expressing daptomycin"></PatentFamily><PatentFamily id="2884508" number="EP-02832379" title="Method for the treatment of biological tissue"></PatentFamily><PatentFamily id="2901783" number="CN-104342379" title="Method for using fosfomycin breeding the high-yield bacterial strain of daptomycin"></PatentFamily><PatentFamily id="2929876" number="US-20150126707" title="Daptomycin analogues and a method for the preparation of daptomycin or a daptomycin analogue"></PatentFamily><PatentFamily id="2937291" number="CN-104511011" title="A a daptomycin sterile powder and its preparation method"></PatentFamily><PatentFamily id="2953858" number="CN-104650189" title="Preparation method of heterogeneous daptomycin"></PatentFamily><PatentFamily id="2961009" number="WO-2015093839" title="New &lt;i&gt;Streptomyces filamentosus&lt;/i&gt; variant and method for producing daptomycin using same"></PatentFamily><PatentFamily id="2961469" number="WO-2015095227" title="Peptidomimetic compounds and antibody-drug conjugates thereof"></PatentFamily><PatentFamily id="2983939" number="CN-104774834" title="Method of using sodium tolerance model to screen glutamic acid high-yield bacterial strain of daptomycin"></PatentFamily><PatentFamily id="3065246" number="WO-2015171225" title="Identification of novel anti-persister activity for &lt;i&gt;Borrelia burgdorferi&lt;/i&gt;"></PatentFamily><PatentFamily id="3069018" number="CN-105001305" title="Method using chromatography technology for extracting high purity daptomycin"></PatentFamily><PatentFamily id="3085101" number="CN-105111285" title="Extraction of daptomycin"></PatentFamily><PatentFamily id="3170140" number="WO-2016059592" title="Stable injectable composition of peptide drugs and process for its preparation"></PatentFamily><PatentFamily id="3178267" number="CN-105481950" title="A extracting method of daptomycin"></PatentFamily><PatentFamily id="3214724" number="CN-105699554" title="High-purity daptomycin lactone hydrolysate and its application"></PatentFamily><PatentFamily id="3258571" number="CN-105779400" title="Fat acid AMP ligase mutant of increasing substrate affinity and application thereof"></PatentFamily><PatentFamily id="3337591" number="CN-103848894" title="Novel compounds containing the structure of daptomycin and a preparation method and uses of the compounds"></PatentFamily><PatentFamily id="3468580" number="CN-106148179" title="Staphylococcus drug-sensitive lath and its preparing method"></PatentFamily><PatentFamily id="3471850" number="WO-2016196791" title="&lt;i&gt;In vivo&lt;/i&gt; photoacoustic and photothermal nano-theranostics of biofilms"></PatentFamily><PatentFamily id="3577229" number="WO-2017049233" title="Lysin polypeptides active against Gram-negative bacteria"></PatentFamily><PatentFamily id="3692010" number="EP-03184126" title="Antibiotic polymethyl methacrylate bone cement"></PatentFamily><PatentFamily id="3698568" number="CN-106821983" title="A preparation method of novel daptomycin coupling transdermal preparation"></PatentFamily><PatentFamily id="3710630" number="CN-106866791" title="Preparation method of high-purity daptomycin lactone hydrolysate"></PatentFamily><PatentFamily id="3710631" number="CN-106866790" title="Preparation method of rs-5/6, rs-7 and rs-7a/7b impurity of daptomycin"></PatentFamily><PatentFamily id="3710632" number="CN-106866789" title="Method for separating and purifying rs-8 daptomycin impurities"></PatentFamily><PatentFamily id="3729914" number="CN-106943587" title="A daptomycin for injection frozen-dry powder injection and its preparing technology"></PatentFamily><PatentFamily id="374857" number="CN-102242073" title="Method for preparing daptomycin by fermentation"></PatentFamily><PatentFamily id="377174" number="CN-102675426" title="Extraction and purification method of daptomycin"></PatentFamily><PatentFamily id="3830918" number="CN-107267434" title="A high yield daptomycin rose spore streptomycete l31 and its construction method"></PatentFamily><PatentFamily id="3884950" number="CN-104387444" title="A preparation method of rs-2 high-purity sample of daptomycin impurities"></PatentFamily><PatentFamily id="394345" number="WO-00018419" title="Methods for administration of antibiotics"></PatentFamily><PatentFamily id="4001999" number="WO-2018064150" title="Microbead compositions and methods for delivering an agent"></PatentFamily><PatentFamily id="4019488" number="CN-107868120" title="A purification method of daptomycin"></PatentFamily><PatentFamily id="4029359" number="WO-2018073269" title="Liquid formulations of daptomycin"></PatentFamily><PatentFamily id="4095364" number="WO-2018108896" title="Process for the purification of lipopolypeptide antibiotics"></PatentFamily><PatentFamily id="4131087" number="CN-108250270" title="A enrichment method for extracting daptomycin from fermentation liquor"></PatentFamily><PatentFamily id="4147771" number="CN-108342436" title="A fermentation preparation of daptomycin method"></PatentFamily><PatentFamily id="4147772" number="CN-108342435" title="A fermentation preparation of daptomycin method"></PatentFamily><PatentFamily id="4317844" number="CN-108941607" title="A method for preparing nano gold particles using daptomycin as a template"></PatentFamily><PatentFamily id="4321103" number="WO-2018234301" title="Bacitracin and/or daptomycin combined with cannabidiol for treatment of bacterial infections"></PatentFamily><PatentFamily id="4352950" number="WO-2019014260" title="Blood component potentiation of lytic protein anti-bacterial activity and methods and uses thereof"></PatentFamily><PatentFamily id="436733" number="WO-03014147" title="Novel depsipeptides and process for preparing same"></PatentFamily><PatentFamily id="4419461" number="WO-2019043008" title="Daptomycin formulations"></PatentFamily><PatentFamily id="4477145" number="CN-109593808" title="Daptomycin fermentation culture medium and its preparation method"></PatentFamily><PatentFamily id="4490874" number="CN-109666065" title="A method for fast preparing high purity of daptomycin method"></PatentFamily><PatentFamily id="518147" number="CN-101899410" title="Streptomyces parvus and application in preparing daptomycin"></PatentFamily><PatentFamily id="551401" number="WO-2006130629" title="Daptomycin for the treatment of biofilm and catheter salvage"></PatentFamily><PatentFamily id="603310" number="CN-102586147" title="Screening method of rose spore streptomycete with high-yielding daptomycin"></PatentFamily><PatentFamily id="626872" number="WO-2007108841" title="Method for identifying drug-sensitizing antisense DNA fragments and use thereof"></PatentFamily><PatentFamily id="726545" number="CN-101235080" title="Synthetic method of daptomycin"></PatentFamily><PatentFamily id="940656" number="WO-02059145" title="Methods for preparing purified lipopeptides"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>30</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>10</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>57</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>5</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sichuan University" id="1003379"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="North China Pharmaceutical Group Corp (NCPC)" id="1005667"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Xiamen University" id="1006185"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Memphis" id="1006336"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jiangsu Hengrui Medicine Co Ltd" id="1006925"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Peking University" id="1009044"></CompanyLink><CountAsOwner>10</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>10</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lunan Pharmaceutical Co Ltd" id="1009275"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Achaogen Inc" id="1009647"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang Medicine Co Ltd" id="1012520"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang University" id="1014561"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="The University of Arkansas System" id="1018113"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Aida Pharmaceuticals Inc" id="1020321"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Yanshan University" id="1026342"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Anhui BBCA Biochemical Co Ltd" id="1027049"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Intas Pharmaceuticals Ltd" id="1028220"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Fujian Institute of Microbiology" id="1028606"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Heraeus Holding GmbH" id="1035509"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Big Bio Co Ltd" id="1041805"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Eagle Pharmaceuticals Inc" id="1041920"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Southwest University" id="1052147"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="China National Pharmaceutical Group Corporation" id="1055632"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Xellia Pharmaceuticals AS" id="1056731"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chengdu Yacht Biotechnology Co Ltd" id="1057904"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="ContraFect Corp" id="1061553"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Multiple Sclerosis Treatment Center" id="1061605"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Somerset Group Enterprises Inc" id="1071470"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Laiyi Center For Biopharmaceutical R&amp;D" id="1073589"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Suzhou Nanomicro Technology Company Limited" id="1075307"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lunan Xinshidai Biotech Co Ltd" id="1077264"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shandong Lubei Pharmaceutical Co Ltd" id="1079449"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Huadong Medicine Co Ltd" id="1080476"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Academy of Military Medical Sciences" id="1098665"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zimmer Biomet Holdings Inc" id="1106763"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Anhui Fengyuan Fermentation Technology Engineering Research Co Ltd" id="1111228"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lisure Science (Suzhou) Co ltd" id="1114703"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Agila Specialties Private" id="1136215"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tianjin Lingshi Biotechnology Development Co Ltd" id="1146770"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alliance Medical Group" id="1148001"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bioventures LLC" id="1151752"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hospira Australia Pty Ltd" id="1151879"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dazhou Vocational and Technical College" id="1153319"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AstraZeneca plc" id="14190"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Gilead Sciences Inc" id="16450"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Eli Lilly &amp; Co" id="17810"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck &amp; Co Inc" id="18077"></CompanyLink><CountAsOwner>13</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>13</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mylan NV" id="18439"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pfizer Inc" id="18767"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>4</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Roche Holding AG" id="19446"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Stada Arzneimittel AG" id="20236"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teva Pharmaceutical Industries Ltd" id="20348"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of British Columbia" id="20532"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Boston University" id="20539"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johns Hopkins University" id="20596"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universita degli Studi di Milano" id="20625"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Auckland" id="20647"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Utah" id="20690"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Altus Pharmaceuticals Inc" id="20740"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>10</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>10</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="China Pharmaceutical University" id="21231"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dong Kook Pharmaceutical Co Ltd" id="21257"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="MorphoSys AG" id="21404"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="The University of Hong Kong" id="22487"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chinese Academy of Sciences" id="23863"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Gnosis Srl" id="28043"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Biocon Ltd" id="28769"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="International Health Management Associates Inc" id="28864"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dr Reddy's Laboratories Ltd" id="29387"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Livzon Pharmaceutical Group Inc" id="29608"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Fidia Group" id="29994"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Medichem SA" id="30595"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Strides Pharma Science Limited" id="30808"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="BIOTRONIK SE &amp; Co" id="31522"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tianjin University" id="CM27908"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Southern Denmark" id="DOL1000153"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput>